Bart Staels

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4207627/publications.pdf

Version: 2024-02-01

796 papers	87,669 citations	235 149 h-index	636 264 g-index
830 all docs	830 docs citations	830 times ranked	80654 citing authors

#	Article	IF	Citations
1	Apolipoprotein F is reduced in humans with steatosis and controls plasma triglycerideâ€rich lipoprotein metabolism. Hepatology, 2023, 77, 1287-1302.	3.6	3
2	Integrative study of diet-induced mouse models of NAFLD identifies PPARÎ± as a sexually dimorphic drug target. Gut, 2022, 71, 807-821.	6.1	26
3	Bile acids contribute to the development of non-alcoholic steatohepatitis in mice. JHEP Reports, 2022, 4, 100387.	2.6	28
4	Synthesis and biological studies of â€œPolycerasoidolâ€•and â€œtrans-Î´-Tocotrienolic acidâ€•derivatives as PPARÎ± and/or PPARÎ³ agonists. Bioorganic and Medicinal Chemistry, 2022, 53, 116532.	1.4	5
5	Identification of indole-based activators of insulin degrading enzyme. European Journal of Medicinal Chemistry, 2022, 228, 113982.	2.6	3
6	Posttranscriptional Regulation of the Human LDL Receptor by the U2-Spliceosome. Circulation Research, 2022, 130, 80-95.	2.0	9
7	Enterocyte superoxide dismutase 2 deletion drives obesity. IScience, 2022, 25, 103707.	1.9	4
8	Innovative transdermal delivery of insulin using gelatin methacrylate-based microneedle patches in mice and mini-pigs. Nanoscale Horizons, 2022, 7, 174-184.	4.1	21
9	The Circadian Clock and Obesity. Handbook of Experimental Pharmacology, 2022, , 29-56.	0.9	2
10	The conundrum of the functional relationship between transcription factors and chromatin. Epigenomics, 2022, , .	1.0	0
11	Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption. , 2022, 1, 299-312.		5
12	Circulating Monocyte Subsets and Transcatheter Aortic Valve Replacement. International Journal of Molecular Sciences, 2022, 23, 5303.	1.8	4
13	Diabetes mellitus and cardiovascular mortality across the spectrum of aortic stenosis. Heart, 2022, 108, 1815-1821.	1.2	6
14	Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism. Nutrients, 2022, 14, 2707.	1.7	8
15	Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH). Hepatology, 2021, 73, 920-936.	3.6	39
16	Deletion of fibroblast activation protein provides atheroprotection. Cardiovascular Research, 2021, 117, 1060-1069.	1.8	20
17	Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease. Acta Diabetologica, 2021, 58, 319-327.	1.2	4
18	Apolipoprotein A5 controls fructose-induced metabolic dysregulation in mice. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 972-978.	1.1	3

#	Article	IF	Citations
19	NASH-related increases in plasma bile acid levels depend on insulin resistance. JHEP Reports, 2021, 3, 100222.	2.6	24
20	Beyond the Rule of 5: Impact of PEGylation with Various Polymer Sizes on Pharmacokinetic Properties, Structureâ€“Properties Relationships of mPEGylated Small Agonists of TGR5 Receptor. Journal of Medicinal Chemistry, 2021, 64, 1593-1610.	2.9	9
21	Cholangiopathy and Biliary Fibrosis in Cyp2c70-Deficient Mice Are Fully Reversed by Ursodeoxycholic Acid. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1045-1069.	2.3	31
22	Alterations in Rev-ERBÎ±/BMAL1 ratio and glycated hemoglobin in rotating shift workers: the EuRhythDia study. Acta Diabetologica, 2021, 58, 1111-1117.	1.2	22
23	Light therapy improves diurnal blood pressure control in night shift workers via reduction of catecholamines: the EuRhythDia study. Journal of Hypertension, 2021, 39, 1678-1688.	0.3	11
24	Characterization of one anastomosis gastric bypass and impact of biliary and common limbs on bile acid and postprandial glucose metabolism in a minipig model. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E772-E783.	1.8	8
25	IFNÎ³-producing NK cells in adipose tissue are associated with hyperglycemia and insulin resistance in obese women. International Journal of Obesity, 2021, 45, 1607-1617.	1.6	8
26	Day-Time Declamping Is Associated with Better Outcomes in Kidney Transplantation: The Circarein Study. Journal of Clinical Medicine, 2021, 10, 2322.	1.0	8
27	Vascular Endothelial Damage in the Pathogenesis of Organ Injury in Severe COVID-19. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1760-1773.	1.1	82
28	PPARs in liver physiology. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166097.	1.8	33
29	PPAR control of metabolism and cardiovascular functions. Nature Reviews Cardiology, 2021, 18, 809-823.	6.1	299
30	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. Journal of Hepatology, 2021, 74, 1344-1354.	1.8	77
31	Why is elevation of serum cholesterol associated with exposure to perfluoroalkyl substances (PFAS) in humans? A workshop report on potential mechanisms. Toxicology, 2021, 459, 152845.	2.0	40
32	Hypothalamic bile acid-TGR5 signaling protects from obesity. Cell Metabolism, 2021, 33, 1483-1492.e10.	7.2	79
33	Regulation of PPARÎ± by APP in Alzheimer disease affects the pharmacological modulation of synaptic activity. JCI Insight, 2021, 6, .	2.3	8
34	Hepatic sexual dimorphism â€" implications for non-alcoholic fatty liver disease. Nature Reviews Endocrinology, 2021, 17, 662-670.	4.3	41
35	The ALGOVUE Clinical Trial: Effects of the Daily Consumption of Eggs Enriched with Lutein and Docosahexaenoic Acid on Plasma Composition and Macular Pigment Optical Density. Nutrients, 2021, 13, 3347.	1.7	9
36	An optimized protocol with a stepwise approach to identify specific nuclear receptor ligands from cultured mammalian cells. STAR Protocols, 2021, 2, 100658.	0.5	2

#	Article	IF	Citations
37	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategiesâ€"a consensus statement from the European Atherosclerosis Society. European Heart Journal, 2021, 42, 4791-4806.	1.0	303
38	Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2021, 123, 154844.	1.5	20
39	Synthesis of 2-Prenylated Alkoxylated Benzopyrans by Hornerâ€"Wadsworthâ€"Emmons Olefination with PPARÎ±/Î³ Agonist Activity. ACS Medicinal Chemistry Letters, 2021, 12, 1783-1786.	1.3	5
40	Lipidomics and metabolomics signatures of SARS-CoV-2 mediators/receptors in peripheral leukocytes, jejunum and colon. Computational and Structural Biotechnology Journal, 2021, 19, 6080-6089.	1.9	7
41	The hepatic compensatory response to elevated systemic sulfide promotes diabetes. Cell Reports, 2021, 37, 109958.	2.9	9
42	Farnesoid X Receptor Activation in Brain Alters Brown Adipose Tissue Function via the Sympathetic System. Frontiers in Molecular Neuroscience, 2021, 14, 808603.	1.4	9
43	Peroxisomal Î²-oxidation acts as a sensor for intracellular fatty acids and regulates lipolysis. Nature Metabolism, 2021, 3, 1648-1661.	5.1	70
44	Electrothermal patches driving the transdermal delivery of insulin. Nanoscale Horizons, 2020, 5, 663-670.	4.1	30
45	Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets. Diabetes, 2020, 69, 902-914.	0.3	42
46	Bile acids associate with glucose metabolism, but do not predict conversion from impaired fasting glucose to diabetes. Metabolism: Clinical and Experimental, 2020, 103, 154042.	1.5	21
47	Control of Cell Identity by the Nuclear Receptor HNF4 in Organ Pathophysiology. Cells, 2020, 9, 2185.	1.8	40
48	Timed physical exercise does not influence circadian rhythms and glucose tolerance in rotating night shift workers: The EuRhythDia study. Diabetes and Vascular Disease Research, 2020, 17, 147916412095061.	0.9	8
49	CDKN2A/p16INK4a suppresses hepatic fatty acid oxidation through the AMPKÎ±2-SIRT1-PPARÎ± signaling pathway. Journal of Biological Chemistry, 2020, 295, 17310-17322.	1.6	17
50	Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Molecular Metabolism, 2020, 42, 101092.	3.0	197
51	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. The Lancet Gastroenterology and Hepatology, 2020, 5, 970-985.	3.7	142
52	Endotheliopathy Is Induced by Plasma From Critically Ill Patients and Associated With Organ Failure in Severe COVID-19. Circulation, 2020, 142, 1881-1884.	1.6	69
53	GIANT: galaxy-based tool for interactive analysis of transcriptomic data. Scientific Reports, 2020, 10, 19835.	1.6	11
54	Deletion of the nuclear receptor RORÎ± in macrophages does not modify the development of obesity, insulin resistance and NASH. Scientific Reports, 2020, 10, 21095.	1.6	6

#	Article	IF	Citations
55	Saturated Fatty Acids Promote GDF15 Expression in Human Macrophages through the PERK/eIF2/CHOP Signaling Pathway. Nutrients, 2020, 12, 3771.	1.7	14
56	Altered PPARÎ³ Expression Promotes Myelin-Induced Foam Cell Formation in Macrophages in Multiple Sclerosis. International Journal of Molecular Sciences, 2020, 21, 9329.	1.8	16
57	Human Aortic Valve Interstitial Cells Display Proangiogenic Properties During Calcific Aortic Valve Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 41, 415-429.	1.1	12
58	Perspectives on the use of super-enhancers as a defining feature of cell/tissue-identity genes. Epigenomics, 2020, 12, 715-723.	1.0	5
59	Incretin combination therapy for the treatment of nonâ€alcoholic steatohepatitis. Diabetes, Obesity and Metabolism, 2020, 22, 1328-1338.	2.2	26
60	Cross-omics analysis revealed gut microbiome-related metabolic pathways underlying atherosclerosis development after antibiotics treatment. Molecular Metabolism, 2020, 36, 100976.	3.0	46
61	Analysis of the association of MPO and MMP-9 with stroke severity and outcome. Neurology, 2020, 95, e97-e108.	1.5	42
62	Pirfenidone Is an Agonistic Ligand for PPARÎ± and Improves NASH by Activation of SIRT1/LKB1/pAMPK. Hepatology Communications, 2020, 4, 434-449.	2.0	33
63	Differential unfolded protein response in skeletal muscle from non-diabetic glucose tolerant or intolerant patients with obesity before and after bariatric surgery. Acta Diabetologica, 2020, 57, 819-826.	1.2	1
64	Microbiome Modulation of the Host Adaptive Immunity through Bile Acid Modification. Cell Metabolism, 2020, 31, 445-447.	7.2	22
65	The nuclear receptor FXR inhibits Glucagon-Like Peptide-1 secretion in response to microbiota-derived Short-Chain Fatty Acids. Scientific Reports, 2020, 10, 174.	1.6	45
66	Effect of 6-Benzoyl-benzothiazol-2-one scaffold on the pharmacological profile of Î±-alkoxyphenylpropionic acid derived PPAR agonists. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 524-538.	2.5	4
67	Sirt6 deletion in bone marrow-derived cells increases atherosclerosis â€“ Central role of macrophage scavenger receptor 1. Journal of Molecular and Cellular Cardiology, 2020, 139, 24-32.	0.9	26
68	Clinical significance of electrocardiographic markers of myocardial damage prior to aortic valve replacement. International Journal of Cardiology, 2020, 307, 130-135.	0.8	10
69	Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance. Nature Communications, 2020, 11, 1891.	5.8	63
70	Plasma BCAA Changes in Patients With NAFLD Are Sex Dependent. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2311-2321.	1.8	39
71	Endoplasmic reticulum stress actively suppresses hepatic molecular identity in damaged liver. Molecular Systems Biology, 2020, 16, e9156.	3.2	22
72	Obesity Paradox in the Clinical Significance of Effective Prosthetic Orifice Area After Aortic Valve Replacement. JACC: Cardiovascular Imaging, 2019, 12, 208-210.	2.3	14

#	Article	IF	Citations
73	The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release. Cell Reports, 2019, 28, 1447-1454.e4.	2.9	25
74	Mathematical models converge on PGC1Î± as the key metabolic integrator of SIRT1 and AMPK regulation of the circadian clock. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 13171-13172.	3.3	7
75	FXR overexpression alters adipose tissue architecture in mice and limits its storage capacity leading to metabolic derangements. Journal of Lipid Research, 2019, 60, 1547-1561.	2.0	19
76	Glycogen Dynamics Drives Lipid Droplet Biogenesis during Brown Adipocyte Differentiation. Cell Reports, 2019, 29, 1410-1418.e6.	2.9	31
77	Transcription profiling in the liver of undernourished male rat offspring reveals altered lipid metabolism pathways and predisposition to hepatic steatosis. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E1094-E1107.	1.8	6
78	Mechanisms Underlying the Functional Cooperation Between PPARÎ± and GRÎ± to Attenuate Inflammatory Responses. Frontiers in Immunology, 2019, 10, 1769.	2.2	12
79	Brain insulin response and peripheral metabolic changes in a Tau transgenic mouse model. Neurobiology of Disease, 2019, 125, 14-22.	2.1	16
80	Hepatic PPARÎ± is critical in the metabolic adaptation to sepsis. Journal of Hepatology, 2019, 70, 963-973.	1.8	53
81	Near-infrared light activatable hydrogels for metformin delivery. Nanoscale, 2019, 11, 15810-15820.	2.8	30
82	Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients. BMC Medical Genomics, 2019, 12, 80.	0.7	22
83	Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution. Nature Metabolism, 2019, 1, 604-614.	5.1	102
84	FRI-355-Elafibranor, a drug candidate for first line NASH monotherapy and a universal backbone for drug combination treatment. Journal of Hepatology, 2019, 70, e551.	1.8	2
85	Metabolic and Innate Immune Cues Merge into a Specific Inflammatory Response via the UPR. Cell, 2019, 177, 1201-1216.e19.	13.5	100
86	Dietary Sargassum fusiforme improves memory and reduces amyloid plaque load in an Alzheimerâ€™s disease mouse model. Scientific Reports, 2019, 9, 4908.	1.6	51
87	The circadian clock and liver function in health and disease. Journal of Hepatology, 2019, 71, 200-211.	1.8	128
88	Liver-specific RORÎ± deletion does not affect the metabolic susceptibility to western style diet feeding. Molecular Metabolism, 2019, 23, 82-87.	3.0	4
89	Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARÎ±. Nature Communications, 2019, 10, 1684.	5.8	48
90	Understanding lipid metabolism through hepatic steat-omics. Nature Reviews Endocrinology, 2019, 15, 321-322.	4.3	1

#	Article	IF	Citations
91	The LPS/D-Galactosamine-Induced Fulminant Hepatitis Model to Assess the Role of Ligand-Activated Nuclear Receptors on the NLRP3 Inflammasome Pathway In Vivo. Methods in Molecular Biology, 2019, 1951, 189-207.	0.4	7
92	Synthesis of benzopyran derivatives as PPARÎ± and/or PPARÎ³ activators. Bioorganic and Medicinal Chemistry, 2019, 27, 115162.	1.4	6
93	Bile acid alterations in nonalcoholic fatty liver disease, obesity, insulin resistance and type 2 diabetes: what do the human studies tell?. Current Opinion in Lipidology, 2019, 30, 244-254.	1.2	39
94	ATF6Î± downregulation of PPARÎ± promotes lipotoxicity-induced tubulointerstitial fibrosis. Kidney International, 2019, 95, 577-589.	2.6	86
95	Epicardial fat amount is associated with the magnitude of left ventricular remodeling in aortic stenosis. International Journal of Cardiovascular Imaging, 2019, 35, 267-273.	0.7	13
96	Keratinocyte Expression of A20/TNFAIP3 Controls Skin Inflammation Associated with Atopic Dermatitis and Psoriasis. Journal of Investigative Dermatology, 2019, 139, 135-145.	0.3	42
97	Sex-regulated gene dosage effect of PPARÎ± on synaptic plasticity. Life Science Alliance, 2019, 2, e201800262.	1.3	16
98	Nuclear Receptor Subfamily 1 Group D Member 1 Regulates Circadian Activity of NLRP3 Inflammasome to Reduce the Severity of Fulminant Hepatitis in Mice. Gastroenterology, 2018, 154, 1449-1464.e20.	0.6	144
99	Increased Hepatic PDGF-AA Signaling Mediates Liver Insulin Resistance in Obesity-Associated Type 2 Diabetes. Diabetes, 2018, 67, 1310-1321.	0.3	64
100	Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction. Gut, 2018, 67, 271-283.	6.1	150
101	Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-ErbÎ± antagonism: a single-centre propensity-matched cohort study and a randomised study. Lancet, The, 2018, 391, 59-69.	6.3	244
102	Risperidone-induced metabolic dysfunction is attenuated by Curcuma longa extract administration in mice. Metabolic Brain Disease, 2018, 33, 63-77.	1.4	11
103	Organizing combinatorial transcription factor recruitment at cis-regulatory modules. Transcription, 2018, 9, 233-239.	1.7	10
104	Combinatorial regulation of hepatic cytoplasmic signaling and nuclear transcriptional events by the OGT/REV-ERBÎ± complex. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11033-E11042.	3.3	35
105	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Associationâ€“European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254.	1.0	171
106	Time to Check the Clock in Cardiovascular Research and Medicine. Circulation Research, 2018, 123, 648-650.	2.0	12
107	Retinoids Issued from Hepatic Stellate Cell Lipid Droplet Loss as Potential Signaling Molecules Orchestrating a Multicellular Liver Injury Response. Cells, 2018, 7, 137.	1.8	30
108	Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. Atherosclerosis, 2018, 278, 82-90.	0.4	27

#	Article	IF	Citations
109	Daytime variations in perioperative myocardial injury â€“ Authors' reply. Lancet, The, 2018, 391, 2106.	6.3	0
110	Molecular Actions of PPARÎ± in Lipid Metabolism and Inflammation. Endocrine Reviews, 2018, 39, 760-802.	8.9	420
111	Peri-operative acute kidney injury upon cardiac surgery time-of-day. International Journal of Cardiology, 2018, 272, 54-59.	0.8	9
112	The Nuclear Receptor Rev-erb-Î± Controls the Development of Vascular Calcification. Atherosclerosis Supplements, 2018, 32, 107.	1.2	0
113	The nuclear bile acid receptor FXR is a PKA- and FOXA2-sensitive activator of fasting hepatic gluconeogenesis. Journal of Hepatology, 2018, 69, 1099-1109.	1.8	40
114	Circadian misalignment induces fatty acid metabolism gene profiles and compromises insulin sensitivity in human skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 7789-7794.	3.3	138
115	A deep-learning approach for pattern recognition allows rapid and reproducible quantification of histological NASH parameters: Integration into the QuPath platform. Journal of Hepatology, 2018, 68, S123.	1.8	3
116	Arterial Pulsatility and Circulating vonÂWillebrand Factor in Patients onÂMechanical CirculatoryÂSupport. Journal of the American College of Cardiology, 2018, 71, 2106-2118.	1.2	86
117	MuscleJ: a high-content analysis method to study skeletal muscle with a new Fiji tool. Skeletal Muscle, 2018, 8, 25.	1.9	105
118	Endospanin-2 enhances skeletal muscle energy metabolism and running endurance capacity. JCI Insight, 2018, 3, .	2.3	4
119	Alternative macrophages in atherosclerosis: not always protective!. Journal of Clinical Investigation, 2018, 128, 910-912.	3.9	37
120	Development and implementation of a cell-based assay to discover agonists of the nuclear receptor REV-ERBÎ±. Journal of Biological Methods, 2018, 5, e94.	1.0	10
121	Rev-erb-Î± : une cible thÃ©rapeutique contre la perte de masse musculaire ?. Les Cahiers De Myologie, 2018, , 43-44.	0.0	0
122	Roux-en-Y gastric bypass increases systemic but not portal bile acid concentrations by decreasing hepatic bile acid uptake in minipigs. International Journal of Obesity, 2017, 41, 664-668.	1.6	21
123	Topical ivermectin improves allergic skin inflammation. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1212-1221.	2.7	44
124	The Sodiumâ€“Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model. Diabetes, 2017, 66, 1030-1040.	0.3	119
125	Inactivation of the Nuclear Orphan Receptor COUP-TFII by Small Chemicals. ACS Chemical Biology, 2017, 12, 654-663.	1.6	13
126	Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. Gastroenterology, 2017, 152, 1679-1694.e3.	0.6	630

#	Article	IF	Citations
127	Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase. Atherosclerosis, 2017, 257, 186-194.	0.4	17
128	The logic of transcriptional regulator recruitment architecture at cis-regulatory modules controlling liver functions. Genome Research, 2017, 27, 985-996.	2.4	22
129	Human Alternative Macrophages Populate Calcified Areas of Atherosclerotic Lesions and Display Impaired RANKL-Induced Osteoclastic Bone Resorption Activity. Circulation Research, 2017, 121, 19-30.	2.0	76
130	Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance. Journal of Medicinal Chemistry, 2017, 60, 4185-4211.	2.9	48
131	Anti-diabetic activity of fused PPARÎ³-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression. European Journal of Medicinal Chemistry, 2017, 137, 310-326.	2.6	7
132	Mitochondria and endoplasmic reticulum: Targets for a better insulin sensitivity in skeletal muscle?. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2017, 1862, 901-916.	1.2	13
133	Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. American Journal of Cardiology, 2017, 120, S28-S36.	0.7	45
134	Drug repurposing screen identifies novel small molecule compounds with potent antifibrotic properties. Journal of Hepatology, 2017, 66, S605.	1.8	4
135	The PPARa-regulated dermatopontin is an important contributor to the liver fibrotic response in mouse models and has relevance to fibrosis progression in non-alcoholic fatty liver disease patients. Journal of Hepatology, 2017, 66, S165.	1.8	0
136	Paired biopsy analysis of human liver transcriptome before and 1 year after bariatric surgery identifies a restricted set of inflammation- and extracellular matrix-related genes as pivotal in NASH and fibrosis pathogenesis. Journal of Hepatology, 2017, 66, S593-S594.	1.8	0
137	Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. American Journal of Medicine, 2017, 130, S30-S39.	0.6	56
138	Leptin induces osteoblast differentiation of human valvular interstitial cells via the Akt and ERK pathways. Acta Diabetologica, 2017, 54, 551-560.	1.2	20
139	PPARÎ² in macrophages and atherosclerosis. Biochimie, 2017, 136, 59-64.	1.3	26
140	DHA-derived oxylipins, neuroprostanes and protectins, differentially and dose-dependently modulate the inflammatory response in human macrophages: Putative mechanisms through PPAR activation. Free Radical Biology and Medicine, 2017, 103, 146-154.	1.3	42
141	The RBM14/CoAA-interacting, long intergenic non-coding RNA Paral1 regulates adipogenesis and coactivates the nuclear receptor PPARÎ³. Scientific Reports, 2017, 7, 14087.	1.6	33
142	Fasting the Microbiota to Improve Metabolism?. Cell Metabolism, 2017, 26, 584-585.	7.2	9
143	Role of the nuclear receptor Rev-erb-alpha in the development of vascular calcification. Atherosclerosis, 2017, 263, e19.	0.4	0
144	375 Psoriasis-like inflammation in K14PPARÎ²/Î´ transgenic mice selectively overexpressing PPARÎ²/Î´ in keratinocytes. Journal of Investigative Dermatology, 2017, 137, S256.	0.3	0

#	Article	IF	Citations
145	The tumour suppressor CDKN2A/p16INK4a regulates adipogenesis and bone marrow-dependent development of perivascular adipose tissue. Diabetes and Vascular Disease Research, 2017, 14, 516-524.	0.9	16
146	Ffar2 expression regulates leukaemic cell growth in vivo. British Journal of Cancer, 2017, 117, 1336-1340.	2.9	12
147	Circadian control of metabolism and pathological consequences of clock perturbations. Biochimie, 2017, 143, 42-50.	1.3	26
148	Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3783-3794.	1.8	78
149	Tau deletion promotes brain insulin resistance. Journal of Experimental Medicine, 2017, 214, 2257-2269.	4.2	158
150	A new non-invasive diagnostic score to monitor change in disease activity and predict fibrosis evolution in patients with NASH. Journal of Hepatology, 2017, 66, S110.	1.8	5
151	Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis. Journal of Hepatology, 2017, 66, S110-S111.	1.8	3
152	Retrograde cholesterol transport in the human Caco-2/TC7 cell line: a model to study trans-intestinal cholesterol excretion in atherogenic and diabetic dyslipidemia. Acta Diabetologica, 2017, 54, 191-199.	1.2	10
153	Intestinal bile acid receptors are key regulators of glucose homeostasis. Proceedings of the Nutrition Society, 2017, 76, 192-202.	0.4	27
154	PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nature Reviews Endocrinology, 2017, 13, 36-49.	4.3	509
155	Rev-erb-Î± regulates atrophy-related genes to control skeletal muscle mass. Scientific Reports, 2017, 7, 14383.	1.6	39
156	Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARÎ±-regulated dermatopontin. JCI Insight, 2017, 2, .	2.3	96
157	Distinct but complementary contributions of PPAR isotypes to energy homeostasis. Journal of Clinical Investigation, 2017, 127, 1202-1214.	3.9	270
158	Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis. PPAR Research, 2016, 2016, 1-5.	1.1	8
159	Peroxisome Proliferator-Activated Receptor Î³ Induces the Expression of Tissue Factor Pathway Inhibitor-1 (TFPI-1) in Human Macrophages. PPAR Research, 2016, 2016, 1-9.	1.1	4
160	Metabolic effects of bile acid sequestration. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 138-144.	1.2	9
161	Comment on Patel et al. ACE2 Deficiency Worsens Epicardial Adipose Tissue Inflammation and Cardiac Dysfunction in Response to Diet-Induced Obesity. Diabetes 2016;65:85â€“95. Diabetes, 2016, 65, e1-e2.	0.3	12
162	Demonstration of a day-night rhythm in human skeletal muscle oxidative capacity. Molecular Metabolism, 2016, 5, 635-645.	3.0	136

#	Article	IF	Citations
163	Transducinâ€like enhancer of splitâ€1 is expressed and functional in human macrophages. FEBS Letters, 2016, 590, 43-52.	1.3	6
164	Innate lymphoid cells contribute to allergic airway disease exacerbation by obesity. Journal of Allergy and Clinical Immunology, 2016, 138, 1309-1318.e11.	1.5	83
165	Influence of Roux-en-Y gastric bypass on plasma bile acid profiles: a comparative study between rats, pigs and humans. International Journal of Obesity, 2016, 40, 1260-1267.	1.6	61
166	PLPNA3 Status in Nash is Associated with Increased Histological Severity at Baseline but Not with Response to Therapy in the Golden-505 Elafibranor Trial. Journal of Hepatology, 2016, 64, S147.	1.8	2
167	A Post-Hoc Analysis ofthe Golden505 Trial Demonstrates Histological and Cardiometabolic Efficacy of Elafibranor-120 Mg in Patients with Moderate or Severe Nash That Are Eligible for Pharmacotherapy. Journal of Hepatology, 2016, 64, S192.	1.8	0
168	RORgt Inhibition in the Liver Prevents Hepatic Fibrosis Progression, a Proof of Concept Study with a Potent, First in Class, Hepatocentric RORgt Inverse Agonist. Journal of Hepatology, 2016, 64, S523.	1.8	1
169	The Identification of Novel Small Molecule Compounds with Potent Anti-Fibrotic Properties by Phenotypic Screening of Primary Human Stellate Cells. Journal of Hepatology, 2016, 64, S712.	1.8	0
170	A New Method including the Quantification of Circulating Mirnas Allows the Efficient Identification of Nash Patients at Risk who should be Treated. Journal of Hepatology, 2016, 64, S717.	1.8	2
171	Impaired histone deacetylases 5 and 6 expression mimics the effects of obesity and hypoxia on adipocyte function. Molecular Metabolism, 2016, 5, 1200-1207.	3.0	25
172	An oxidative stress paradox: time for a conceptual change?. Diabetologia, 2016, 59, 2514-2517.	2.9	5
173	ORP4L Facilitates Macrophage Survival via G-Proteinâ€“Coupled Signaling. Circulation Research, 2016, 119, 1296-1312.	2.0	26
174	Relationship between Baseline Hepatic Disease Severity and the Cardiometabolic and Anti-Inflammatory Effects of Elafibranor in Patients with Non-Alcoholic Steatohepatitis. Journal of Hepatology, 2016, 64, S499-S500.	1.8	1
175	Chromatin recruitment of activated AMPK drives fasting response genes co-controlled by GR and PPARÎ±. Nucleic Acids Research, 2016, 44, 10539-10553.	6.5	56
176	Von Willebrand Factor Multimers during Transcatheter Aortic-Valve Replacement. New England Journal of Medicine, 2016, 375, 335-344.	13.9	128
177	Synchronized human skeletal myotubes of lean, obese and type 2 diabetic patients maintain circadian oscillation of clock genes. Scientific Reports, 2016, 6, 35047.	1.6	35
178	Farnesoid X Receptor and Its Ligands Inhibit the Function of Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2324-2333.	1.1	24
179	Omentin-1, epicardial fat and coronary artery disease. Atherosclerosis, 2016, 255, 224-225.	0.4	0
180	A Mathematical Model of the Liver Circadian Clock Linking Feeding and Fasting Cycles to Clock Function. Cell Reports, 2016, 17, 1087-1097.	2.9	74

#	Article	IF	Citations
181	Perilipin2/adipophilin and ApoA-1 team up to combat atherosclerosis. Cardiovascular Research, 2016, 109, 193-195.	1.8	7
182	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
183	Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. Annual Review of Physiology, 2016, 78, 181-205.	5.6	302
184	Liver X Receptor Regulates Triglyceride Absorption Through Intestinal Down-regulation of Scavenger Receptor Class B, Type 1. Gastroenterology, 2016, 150, 650-658.	0.6	41
185	The novel selective PPARÎ± modulator (SPPARMÎ±) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Atherosclerosis, 2016, 249, 200-208.	0.4	107
186	Elafibranor, an Agonist of the Peroxisome Proliferatorâ^'Activated Receptorâ^'Î± andÂâ^'Î´, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology, 2016, 150, 1147-1159.e5.	0.6	847
187	Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARÎ± expression. Gut, 2016, 65, 1882-1894.	6.1	140
188	Skeletal muscle functions around the clock. Diabetes, Obesity and Metabolism, 2015, 17, 39-46.	2.2	40
189	Cholesterylâ€ester transfer protein (CETP): A Kupffer cell marker linking hepatic inflammation with atherogenic dyslipidemia?. Hepatology, 2015, 62, 1659-1661.	3.6	6
190	Bariatric surgery, lipoprotein metabolism and cardiovascular risk. Current Opinion in Lipidology, 2015, 26, 317-324.	1.2	15
191	The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation. Obesity, 2015, 23, 2066-2074.	1.5	196
192	Temporal changes in bile acid levels and 12Î±-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. International Journal of Obesity, 2015, 39, 806-813.	1.6	79
193	Structural and functional changes in HDL with low grade and chronic inflammation. International Journal of Cardiology, 2015, 188, 111-116.	0.8	60
194	The Sirt1 activator SRT3025 provides atheroprotection in Apoeâ^'/â^' mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. European Heart Journal, 2015, 36, 51-59.	1.0	117
195	Functional genomics of the CDKN2A/B locus in cardiovascular and metabolic disease: what have we learned from GWASs?. Trends in Endocrinology and Metabolism, 2015, 26, 176-184.	3.1	137
196	M1 and M2 macrophage proteolytic and angiogenic profile analysis in atherosclerotic patients reveals a distinctive profile in type 2 diabetes. Diabetes and Vascular Disease Research, 2015, 12, 279-289.	0.9	38
197	Molecular mechanism of PPARÎ± action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. Journal of Hepatology, 2015, 62, 720-733.	1.8	1,028
198	The ubiquitous transcription factor CTCF promotes lineage-specific epigenomic remodeling and establishment of transcriptional networks driving cell differentiation. Nucleus, 2015, 6, 15-18.	0.6	7

#	Article	IF	Citations
199	Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2473-2478.	3.3	310
200	Rapid and Body Weightâ€“Independent Improvement of Endothelial and High-Density Lipoprotein Function After Roux-en-Y Gastric Bypass. Circulation, 2015, 131, 871-881.	1.6	103
201	The coronary artery diseaseâ€associated gene C6ORF105 is expressed in human macrophages under the transcriptional control of PPARÎ³. FEBS Letters, 2015, 589, 461-466.	1.3	17
202	PPARÎ± gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. Journal of Hepatology, 2015, 63, 164-173.	1.8	270
203	Adventitial Tertiary Lymphoid Organs as Potential Source of MicroRNA Biomarkers for Abdominal Aortic Aneurysm. International Journal of Molecular Sciences, 2015, 16, 11276-11293.	1.8	28
204	Role of the nuclear receptor Rev-erb-alpha in the development of atherosclerosis. Atherosclerosis, 2015, 241, e6.	0.4	1
205	The neuron-derived orphan receptor 1 (NOR1) is induced upon human alternative macrophage polarization and stimulates the expression of markers of the M2 phenotype. Atherosclerosis, 2015, 241, 18-26.	0.4	30
206	The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity. Cell Metabolism, 2015, 22, 418-426.	7.2	342
207	Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nature Communications, 2015, 6, 7629.	5.8	274
208	Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nature Medicine, 2015, 21, 512-517.	15.2	536
209	MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids. Journal of Clinical Investigation, 2015, 125, 2497-2509.	3.9	195
210	Atherosclerosis: Recent trials, new targets and future directions. International Journal of Cardiology, 2015, 192, 72-81.	0.8	28
211	SREBF2 -Embedded mir33 Links the Nuclear Bile Acid Receptor FXR to Cholesterol and Lipoprotein Metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 748-749.	1.1	5
212	von Willebrand Factor as a Biological Sensor of Blood Flow to Monitor Percutaneous Aortic Valve Interventions. Circulation Research, 2015, 116, 1193-1201.	2.0	72
213	Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice. Nature Communications, 2015, 6, 8250.	5.8	71
214	From cardiac mitochondrial dysfunction to clinical arrhythmias. International Journal of Cardiology, 2015, 184, 597-599.	0.8	12
215	Ketone Body Therapy Protects From Lipotoxicity and Acute Liver Failure Upon PparÎ± Deficiency. Molecular Endocrinology, 2015, 29, 1134-1143.	3.7	33
216	Screening strategy to generate cell specific recombination: a case report with the RIP-Cre mice. Transgenic Research, 2015, 24, 803-812.	1.3	8

#	Article	IF	Citations
217	Gamma radiation production using channeled positron annihilation in crystals. Laser Physics Letters, 2015, 12, 076002.	0.6	2
218	Meta-Analysis of Abdominal Aortic Aneurysm in Patients With Coronary Artery Disease. American Journal of Cardiology, 2015, 116, 1451-1456.	0.7	31
219	Nuclear bile acid signaling through the farnesoid X receptor. Cellular and Molecular Life Sciences, 2015, 72, 1631-1650.	2.4	92
220	Structureâ€“activity relationships of imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, dual binders of human insulin-degrading enzyme. European Journal of Medicinal Chemistry, 2015, 90, 547-567.	2.6	24
221	Macrophage subsets in atherosclerosis. Nature Reviews Cardiology, 2015, 12, 10-17.	6.1	501
222	Emerging Small Molecule Drugs. Handbook of Experimental Pharmacology, 2015, 224, 617-630.	0.9	7
223	GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. Expert Opinion on Investigational Drugs, 2014, 23, 1441-1448.	1.9	27
224	Liver X receptor activation decreases chylomicron assembly and improves post-prandial triglyceridemia via intestinal sr-bi downregulation. Atherosclerosis, 2014, 235, e33.	0.4	0
225	<scp>PPAR</scp>Î± is involved in the multitargeted effects of a pretreatment with atorvastatin in experimental stroke. Fundamental and Clinical Pharmacology, 2014, 28, 294-302.	1.0	12
226	Glucose sensing O-GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR). Hepatology, 2014, 59, 2022-2033.	3.6	55
227	Neuroprostanes, produced by free-radical mediated peroxidation of DHA, inhibit the inflammatory response of human macrophages. Free Radical Biology and Medicine, 2014, 75, S15.	1.3	14
228	The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gammaâ€“associated adverse cardiac effects. Diabetes and Vascular Disease Research, 2014, 11, 440-447.	0.9	31
229	A dynamic CTCF chromatin binding landscape promotes DNA hydroxymethylation and transcriptional induction of adipocyte differentiation. Nucleic Acids Research, 2014, 42, 10943-10959.	6.5	71
230	Impact of Endotoxin Challenge in Obese Pigs. Shock, 2014, 41, 546-553.	1.0	10
231	Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. Journal of Clinical Investigation, 2014, 124, 1037-1051.	3.9	121
232	Hepatic trans-Golgi action coordinated by the GTPase ARFRP1 is crucial for lipoprotein lipidation and assembly. Journal of Lipid Research, 2014, 55, 41-52.	2.0	15
233	HDL does not influence the polarization of human monocytes toward an alternative phenotype. International Journal of Cardiology, 2014, 172, 179-184.	0.8	23
234	DCo(H2)ding the Metabolic Functions of SIRT1 in the Intestine. Gastroenterology, 2014, 146, 893-896.	0.6	1

#	Article	IF	Citations
235	Failing FXR expression in the liver links aging to hepatic steatosis. Journal of Hepatology, 2014, 60, 689-690.	1.8	15
236	P263 STEATOSIS-INDEPENDENT PREVENTION OF LIVER FIBROSIS VIA THE TRANSREPRESSIVE ACTIVITY OF PPARa. Journal of Hepatology, 2014, 60, S152-S153.	1.8	0
237	Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-Î² hydrolysis. European Journal of Medicinal Chemistry, 2014, 79, 184-193.	2.6	27
238	Alternative human liver transcripts of TCF7L2 bind to the gluconeogenesis regulator HNF4Î± at the protein level. Diabetologia, 2014, 57, 785-796.	2.9	33
239	Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis, 2014, 232, 346-360.	0.4	419
240	Cdkn2a/p16Ink4a Regulates Fasting-Induced Hepatic Gluconeogenesis Through the PKA-CREB-PGC1Î± Pathway. Diabetes, 2014, 63, 3199-3209.	0.3	36
241	Cell-Specific Dysregulation of MicroRNA Expression in Obese White Adipose Tissue. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2821-2833.	1.8	55
242	CX3CL1 (fractalkine) and its receptor CX3CR1 regulate atopic dermatitis by controlling effector T cell retention in inflamed skin. Journal of Experimental Medicine, 2014, 211, 1185-1196.	4.2	49
243	Peroxisome Proliferator-activated Receptor Î³ Regulates Genes Involved in Insulin/Insulin-like Growth Factor Signaling and Lipid Metabolism during Adipogenesis through Functionally Distinct Enhancer Classes. Journal of Biological Chemistry, 2014, 289, 708-722.	1.6	39
244	Adipose Tissue Macrophages (ATM) of obese patients are releasing increased levels of prolactin during an inflammatory challenge: A role for prolactin in diabesity?. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 584-593.	1.8	26
245	HDL in Children with CKD Promotes Endothelial Dysfunction and an Abnormal Vascular Phenotype. Journal of the American Society of Nephrology: JASN, 2014, 25, 2658-2668.	3.0	97
246	Macrophage phenotypes in atherosclerosis. Immunological Reviews, 2014, 262, 153-166.	2.8	454
247	SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus. Obesity, 2014, 22, 1309-1316.	1.5	33
248	Efficacy and safety of initial combination treatment with sitagliptin and pioglitazoneâ€"a factorial study. Diabetes, Obesity and Metabolism, 2014, 16, 223-230.	2.2	33
249	Giardia muris Infection in Mice Is Associated with a Protective Interleukin 17A Response and Induction of Peroxisome Proliferator-Activated Receptor Alpha. Infection and Immunity, 2014, 82, 3333-3340.	1.0	56
250	Effects of the PPAR-Î± Agonist Fenofibrate on Acute and Short-Term Consequences of Brain Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 542-551.	2.4	51
251	Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization. Trends in Endocrinology and Metabolism, 2014, 25, 235-244.	3.1	43
252	Myocardial Contractile Dysfunction Is Associated With Impaired Mitochondrial Function and Dynamics in Type 2 Diabetic but Not in Obese Patients. Circulation, 2014, 130, 554-564.	1.6	237

#	Article	IF	Citations
253	miR-206 controls LXRÎ± expression and promotes LXR-mediated cholesterol efflux in macrophages. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 827-835.	1.2	35
254	Macrophage Phenotypes and Their Modulation in Atherosclerosis. Circulation Journal, 2014, 78, 1775-1781.	0.7	163
255	Macrophage-specific inactivation of the nuclear receptor ROR-alpha leads to increased atherosclerosis in mouse. Atherosclerosis, 2014, 235, e20.	0.4	0
256	MiR-206 controls LXR-alpha expression and promotes LXR-mediated cholesterol efflux in macrophages. Atherosclerosis, 2014, 235, e39.	0.4	0
257	Apolipoprotein a5-deficiency promotes cardiac glucose metabolism and protects against acute myocardial stresses. Atherosclerosis, 2014, 235, e45.	0.4	0
258	The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice. Hepatology, 2014, 60, 1593-1606.	3.6	116
259	Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 2014, 59, 121-129.	3.6	141
260	O-GlcNAcylation Links ChREBP and FXR to Glucose-Sensing. Frontiers in Endocrinology, 2014, 5, 230.	1.5	28
261	Beneficial Metabolic Effects of Rapamycin Are Associated with Enhanced Regulatory Cells in Diet-Induced Obese Mice. PLoS ONE, 2014, 9, e92684.	1.1	51
262	Sox17 Regulates Liver Lipid Metabolism and Adaptation to Fasting. PLoS ONE, 2014, 9, e104925.	1.1	15
263	Von Willebrand Factor As a Biological Sensor of Blood Flow in Percutaneous Cardiac Procedures. Blood, 2014, 124, 474-474.	0.6	0
264	The Hepatic Orosomucoid/Î±1-Acid Glycoprotein Gene Cluster Is Regulated by the Nuclear Bile Acid Receptor FXR. Endocrinology, 2013, 154, 3690-3701.	1.4	24
265	Rev-erb-Î± modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nature Medicine, 2013, 19, 1039-1046.	15.2	361
266	PPAR SUMOylation: Some Useful Experimental Tips. Methods in Molecular Biology, 2013, 952, 145-161.	0.4	1
267	A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population. Obesity, 2013, 21, 2138-2145.	1.5	57
268	Mitochondrial Dysfunction as an Arrhythmogenic Substrate. Journal of the American College of Cardiology, 2013, 62, 1466-1473.	1.2	112
269	Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology, 2013, 58, 1941-1952.	3.6	355
270	Liver X Receptor Activation Stimulates Iron Export in Human Alternative Macrophages. Circulation Research, 2013, 113, 1196-1205.	2.0	76

#	Article	IF	Citations
271	Palmitate increases Nur77 expression by modulating ZBP89 and Sp1 binding to the Nur77 proximal promoter in pancreatic Î²â€cells. FEBS Letters, 2013, 587, 3883-3890.	1.3	13
272	PPARalpha regulates the production of serum Vaninâ€1 by liver. FEBS Letters, 2013, 587, 3742-3748.	1.3	56
273	Long-term prognostic value of preprocedural adiponectin levels in patients undergoing percutaneous coronary intervention. International Journal of Cardiology, 2013, 168, 4921-4924.	0.8	3
274	Profiling Serum Bile Acid Glucuronides in Humans: Gender Divergences, Genetic Determinants, and Response to Fenofibrate. Clinical Pharmacology and Therapeutics, 2013, 94, 533-543.	2.3	35
275	Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2013, 27, 177-183.	1.2	48
276	1334 CORRELATION OF HUMAN LIVER PPAR GENE EXPRESSION WITH HISTOLOGICAL SEVERITY OF NASH AND ASSOCIATED METABOLIC DERANGEMENTS: RATIONALE FOR TARGETED THERAPY. Journal of Hepatology, 2013, 58, S538.	1.8	0
277	Free leptin, carotid plaque phenotype and relevance to related symptomatology: Insights from the OPAL-Lille carotid endarterectomy study. International Journal of Cardiology, 2013, 168, 4879-4881.	0.8	2
278	Detrimental Effects of Diet-Induced Obesity on Ï„ Pathology Are Independent of Insulin Resistance in Ï„ Transgenic Mice. Diabetes, 2013, 62, 1681-1688.	0.3	88
279	11Î²â€hydroxysteroid dehydrogenase type 1 deficiency in bone marrowâ€derived cells reduces atherosclerosis. FASEB Journal, 2013, 27, 1519-1531.	0.2	41
280	Macrophage Function and Polarization in Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1127-1134.	1.1	66
281	Activation of intestinal peroxisome proliferator-activated receptor-Â increases high-density lipoprotein production. European Heart Journal, 2013, 34, 2566-2574.	1.0	44
282	Farnesoid X Receptor Inhibits the Transcriptional Activity of Carbohydrate Response Element Binding Protein in Human Hepatocytes. Molecular and Cellular Biology, 2013, 33, 2202-2211.	1.1	110
283	Fenofibrate Inhibits Endothelin-1 Expression by Peroxisome Proliferatorâ€“Activated Receptor Î±â€“Dependent and Independent Mechanisms in Human Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 621-628.	1.1	28
284	Role of Proinflammatory CD68 ⁺ Mannose Receptor ^{â^'} Macrophages in Peroxiredoxin-1 Expression and in Abdominal Aortic Aneurysms in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 431-438.	1.1	65
285	Pharmacological interventions in human HDL metabolism. Current Opinion in Lipidology, 2013, 24, 500-509.	1.2	15
286	Retinoids and nuclear retinoid receptors in white and brown adipose tissues: physiopathologic aspects. Hormone Molecular Biology and Clinical Investigation, 2013, 14, 75-86.	0.3	9
287	Endogenous cannabinoid receptor CB1 activation promotes vascular smooth-muscle cell proliferation and neointima formation. Journal of Lipid Research, 2013, 54, 1360-1368.	2.0	23
288	Increased Atherosclerotic Lesions in LDL Receptor Deficient Mice With Hematopoietic Nuclear Receptor Revâ€erbÎ± Knockâ€Down. Journal of the American Heart Association, 2013, 2, e000235.	1.6	44

#	Article	IF	Citations
289	Dual Peroxisome Proliferatorâ€“Activated Receptor Î±/Î´ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects. Diabetes Care, 2013, 36, 2923-2930.	4.3	187
290	Soaping Up Type 2 Diabetes With Bile Acids?. Diabetes, 2013, 62, 3987-3989.	0.3	11
291	Hepatic glucose sensing is required to preserve Î² cell glucose competence. Journal of Clinical Investigation, 2013, 123, 1662-1676.	3.9	118
292	The Elongation Complex Components BRD4 and MLLT3/AF9 Are Transcriptional Coactivators of Nuclear Retinoid Receptors. PLoS ONE, 2013, 8, e64880.	1.1	14
293	PPARs: A Potential Target for a Disease-Modifying Strategy in Stroke. Current Drug Targets, 2013, 14, 752-767.	1.0	23
294	Nur77turing Macrophages in Atherosclerosis. Circulation Research, 2012, 110, 375-377.	2.0	6
295	Tryptophan metabolism activation by indoleamine 2,3-dioxygenase in adipose tissue of obese women: an attempt to maintain immune homeostasis and vascular tone. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2012, 303, R135-R143.	0.9	95
296	Coordinated Regulation of PPAR Expression and Activity through Control of Chromatin Structure in Adipogenesis and Obesity. PPAR Research, 2012, 2012, 1-9.	1.1	32
297	PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E1063-E1069.	1.8	76
298	The Novel Antibacterial Compound Walrycin A Induces Human PXR Transcriptional Activity. Toxicological Sciences, 2012, 127, 225-235.	1.4	9
299	Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. Journal of Lipid Research, 2012, 53, 1723-1737.	2.0	241
300	Genome-Wide Profiling of Liver X Receptor, Retinoid X Receptor, and Peroxisome Proliferator-Activated Receptor Î± in Mouse Liver Reveals Extensive Sharing of Binding Sites. Molecular and Cellular Biology, 2012, 32, 852-867.	1.1	205
301	Human Adipose Tissue Macrophages Display Activation of Cancer-related Pathways. Journal of Biological Chemistry, 2012, 287, 21904-21913.	1.6	60
302	Peroxisome Proliferatorâ€“Activated Receptor-Î³ Activation Induces 11Î²-Hydroxysteroid Dehydrogenase Type 1 Activity in Human Alternative Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 677-685.	1.1	32
303	Impaired alternative macrophage differentiation of peripheral blood mononuclear cells from obese subjects. Diabetes and Vascular Disease Research, 2012, 9, 189-195.	0.9	43
304	General Molecular Biology and Architecture of Nuclear Receptors. Current Topics in Medicinal Chemistry, 2012, 12, 486-504.	1.0	115
305	Response to the Letter by Finn et al. Circulation Research, 2012, 110, .	2.0	3
306	Peroxisome Proliferator-Activated Receptors-Î± and -Î³, and cAMP-Mediated Pathways, Control Retinol-Binding Protein-4 Gene Expression in Brown Adipose Tissue. Endocrinology, 2012, 153, 1162-1173.	1.4	47

#	Article	IF	Citations
307	Effect of Oxime Ether Incorporation in Acyl Indole Derivatives on PPAR Subtype Selectivity. ChemMedChem, 2012, 7, 2179-2193.	1.6	13
308	The human hepatocyte cell lines IHH and HepaRG: models to study glucose, lipid and lipoprotein metabolism. Archives of Physiology and Biochemistry, 2012, 118, 102-111.	1.0	46
309	Synthesis and evaluation of new polyenic compounds as potential PPARs modulators. Organic and Biomolecular Chemistry, 2012, 10, 6169.	1.5	9
310	The Nuclear Orphan Receptor Nur77 Is a Lipotoxicity Sensor Regulating Glucose-Induced Insulin Secretion in Pancreatic Î²-Cells. Molecular Endocrinology, 2012, 26, 399-413.	3.7	38
311	Does endoplasmic reticulum stress participate in APD-induced hepatic metabolic dysregulation?. Neuropharmacology, 2012, 62, 784-796.	2.0	58
312	Thiazolidinediones and PPARÎ³ agonists: time for a reassessment. Trends in Endocrinology and Metabolism, 2012, 23, 205-215.	3.1	342
313	Control of metabolism by nutrient-regulated nuclear receptors acting in the brain. Journal of Steroid Biochemistry and Molecular Biology, 2012, 130, 126-137.	1.2	126
314	Roles of PPARs in NAFLD: Potential therapeutic targets. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 809-818.	1.2	229
315	Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine, 2012, 59, 442-449.	1.4	100
316	Cellâ€derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation?. Journal of Cellular and Molecular Medicine, 2012, 16, 1365-1376.	1.6	65
317	LDL Receptor Knock-Out Mice Are a Physiological Model Particularly Vulnerable to Study the Onset of Inflammation in Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2012, 7, e30668.	1.1	135
318	Naturally improving insulin resistance with amorfrutins. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7136-7137.	3.3	10
319	Dynamic hydroxymethylation of deoxyribonucleic acid marks differentiation-associated enhancers. Nucleic Acids Research, 2012, 40, 8255-8265.	6.5	166
320	DPP-4 inhibitors in the treatment of type 2 diabetes. Biochemical Pharmacology, 2012, 83, 823-832.	2.0	83
321	Bone Marrow p16INK4a-Deficiency Does Not Modulate Obesity, Glucose Homeostasis or Atherosclerosis Development. PLoS ONE, 2012, 7, e32440.	1.1	14
322	Which is the eligible patient to be treated with pioglitazone? The expert view. Journal of Endocrinological Investigation, 2011, 34, 781-787.	1.8	1
323	PPARÎ²/Î´ Activation Induces Enteroendocrine L Cell GLP-1 Production. Gastroenterology, 2011, 140, 1564-1574.	0.6	55
324	Effects of the New Dual PPARÎ±/Î´ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism. Diabetes Care, 2011, 34, 2008-2014.	4.3	155

#	Article	IF	Citations
325	Short-term activation of liver X receptors inhibits osteoblasts but long-term activation does not have an impact on murine bone in vivo. Bone, 2011, 48, 339-346.	1.4	19
326	Liver X Receptor (LXR) activation negatively regulates visfatin expression in macrophages. Biochemical and Biophysical Research Communications, 2011, 404, 458-462.	1.0	10
327	50 PPARA ACTIVATION DIFFERENTLY AFFECTS MICROPARTICLE CONTENT IN ATHEROSCLEROTIC LESIONS AND LIVER OF A MOUSE MODEL OF ATHEROSCLEROSIS AND NASH. Atherosclerosis Supplements, 2011, 12, 11.	1.2	0
328	446 ATHEROSCLEROTIC LESION REMODELLING IN REV-ERBÎ±-DEFICIENT MICE. Atherosclerosis Supplements, 2011, 12, 95.	1.2	0
329	PPARÎ± activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH. Atherosclerosis, 2011, 218, 69-76.	0.4	24
330	839 SERUM APOLIPOPROTEIN CIII LEVELS DECLINE AFTER WEIGHT LOSS INDUCED IMPROVEMENT IN HEPATIC STEATOSIS. Journal of Hepatology, 2011, 54, S335-S336.	1.8	0
331	Control of Gene Expression by the Retinoic Acid-Related Orphan Receptor Alpha in HepG2 Human Hepatoma Cells. PLoS ONE, 2011, 6, e22545.	1.1	27
332	Macrophage polarization in metabolic disorders. Current Opinion in Lipidology, 2011, 22, 365-372.	1.2	157
333	p16INK4a deficiency promotes IL-4â€“induced polarization and inhibits proinflammatory signaling in macrophages. Blood, 2011, 118, 2556-2566.	0.6	89
334	Overview of the Measurement of Lipids and Lipoproteins in Mice. Current Protocols in Mouse Biology, 2011, 1, 265-277.	1.2	2
335	Generation and characterization of a humanized PPARÎ´ mouse model. British Journal of Pharmacology, 2011, 164, 192-208.	2.7	11
336	CIDEA interacts with liver X receptors in white fat cells. FEBS Letters, 2011, 585, 744-748.	1.3	9
337	Control of nuclear receptor activities in metabolism by postâ€translational modifications. FEBS Letters, 2011, 585, 1640-1650.	1.3	53
338	Downregulation of the tumour suppressor p16INK4A contributes to the polarisation of human macrophages toward an adipose tissue macrophage (ATM)-like phenotype. Diabetologia, 2011, 54, 3150-3156.	2.9	31
339	Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver. Naunyn-Schmiedeberg's Archives of Pharmacology, 2011, 383, 423-436.	1.4	35
340	Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology. Neurobiology of Disease, 2011, 43, 486-494.	2.1	137
341	Bile Acid Metabolism and the Pathogenesis of Type 2 Diabetes. Current Diabetes Reports, 2011, 11, 160-166.	1.7	201
342	Obesity resistant mechanisms in the Lean polygenic mouse model as indicated by liver transcriptome and expression of selected genes in skeletal muscle. BMC Genomics, 2011, 12, 96.	1.2	14

#	Article	IF	Citations
343	Coenzyme Q as an Antiadipogenic Factor. Antioxidants and Redox Signaling, 2011, 14, 403-413.	2.5	27
344	Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity. Diabetes, 2011, 60, 1861-1871.	0.3	261
345	Association Between a Thyroid Hormone Receptor-Î± Gene Polymorphism and Blood Pressure but Not With Coronary Heart Disease Risk. American Journal of Hypertension, 2011, 24, 1027-1034.	1.0	12
346	Telomerase Activation in Atherosclerosis and Induction of Telomerase Reverse Transcriptase Expression by Inflammatory Stimuli in Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 245-252.	1.1	80
347	IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data. Nucleic Acids Research, 2011, 39, D534-D538.	6.5	96
348	Circadian Control of Epigenetic Modifications Modulates Metabolism. Circulation Research, 2011, 109, 353-355.	2.0	3
349	Peroxisome Proliferatorâ€“Activated Receptor-Î± Gene Level Differently Affects Lipid Metabolism and Inflammation in Apolipoprotein E2 Knock-In Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1573-1579.	1.1	66
350	Impaired Expression of the Inducible cAMP Early Repressor Accounts for Sustained Adipose CREB Activity in Obesity. Diabetes, 2011, 60, 3169-3174.	0.3	20
351	Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 513-519.	1.1	129
352	Human Atherosclerotic Plaque Alternative Macrophages Display Low Cholesterol Handling but High Phagocytosis Because of Distinct Activities of the PPARÎ³ and LXRÎ± Pathways. Circulation Research, 2011, 108, 985-995.	2.0	318
353	Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes. Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, 381, 427-439.	1.4	61
354	Characterization of new PPARÎ³ agonists: Benzimidazole derivativesâ€”importance of positions 5 and 6, and computational studies on the binding mode. Bioorganic and Medicinal Chemistry, 2010, 18, 5885-5895.	1.4	26
355	Bile Acid Sequestrants for Lipid and Glucose Control. Current Diabetes Reports, 2010, 10, 70-77.	1.7	68
356	Plasma bile acids are not associated with energy metabolism in humans. Nutrition and Metabolism, 2010, 7, 73.	1.3	67
357	Intrahepatic cholesterol influences progression, inhibition and reversal of nonâ€alcoholic steatohepatitis in hyperlipidemic mice. FEBS Letters, 2010, 584, 1001-1005.	1.3	93
358	The nuclear receptor FXR is expressed in pancreatic Î²â€cells and protects human islets from lipotoxicity. FEBS Letters, 2010, 584, 2845-2851.	1.3	80
359	Kupffer cells promote hepatic steatosis via interleukin-1Î²-dependent suppression of peroxisome proliferator-activated receptor Î± activity. Hepatology, 2010, 51, 511-522.	3.6	381
360	Visfatin is induced by peroxisome proliferatorâ€activated receptor gamma in human macrophages. FEBS Journal, 2010, 277, 3308-3320.	2.2	24

#	Article	IF	Citations
361	Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice. Laboratory Investigation, 2010, 90, 1457-1467.	1.7	77
362	Brinster et al. reply. Nature, 2010, 463, E4-E4.	13.7	42
363	Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes, Obesity and Metabolism, 2010, 12, 384-392.	2.2	124
364	KrÃ¼ppel-Like Factor KLF10 Is a Link between the Circadian Clock and Metabolism in Liver. Molecular and Cellular Biology, 2010, 30, 3059-3070.	1.1	95
365	Proteasomal degradation of retinoid X receptor Î± reprograms transcriptional activity of PPARÎ³ in obese mice and humans. Journal of Clinical Investigation, 2010, 120, 1454-1468.	3.9	56
366	The Natural Protective Mechanism Against Hyperglycemia in Vascular Endothelial Cells. Diabetes, 2010, 59, 808-818.	0.3	67
367	Nuclear Receptors Linking Circadian Rhythms and Cardiometabolic Control. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1529-1534.	1.1	67
368	Introduction on the ATVB Review Series â€œNuclear Receptors in Metabolism and Cardiovascular Diseaseâ€. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1504-1505.	1.1	1
369	Bile Acid Sequestrants: Glucose-Lowering Mechanisms. Metabolic Syndrome and Related Disorders, 2010, 8, S-3-S-8.	0.5	23
370	The Farnesoid X Receptor Regulates Adipocyte Differentiation and Function by Promoting Peroxisome Proliferator-activated Receptor-Î³ and Interfering with the Wnt/Î²-Catenin Pathways. Journal of Biological Chemistry, 2010, 285, 36759-36767.	1.6	79
371	SUMOylation of Human Peroxisome Proliferator-activated Receptor Î± Inhibits Its Trans-activity through the Recruitment of the Nuclear Corepressor NCoR. Journal of Biological Chemistry, 2010, 285, 5983-5992.	1.6	78
372	Retinoid X receptors: common heterodimerization partners with distinct functions. Trends in Endocrinology and Metabolism, 2010, 21, 676-683.	3.1	258
373	Fibrates in CVD: a step towards personalised medicine. Lancet, The, 2010, 375, 1847-1848.	6.3	10
374	Fibrates, Glitazones, and Peroxisome Proliferatorâ€“Activated Receptors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 894-899.	1.1	172
375	Residual Risk Reduction Initiative: vÃ½zva ke snÃ¾enÃreziduÃ¡lnÃho vaskulÃ¡rnÃho rizika u pacientÅ¯ s dyslipidemiÃ. Cor Et Vasa, 2010, 52, 212-228.	0.1	0
376	Bile Acids and Metabolic Regulation. Diabetes Care, 2009, 32, S237-S245.	4.3	304
377	Tissue-Specific Roles of ABCA1 Influence Susceptibility to Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 548-554.	1.1	98
378	Despite Antiatherogenic Metabolic Characteristics, SCD1-Deficient Mice Have Increased Inflammation and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 341-347.	1.1	95

#	Article	IF	Citations
379	PPARÎ± blocks glucocorticoid receptor Î±-mediated transactivation but cooperates with the activated glucocorticoid receptor Î± for transrepression on NF-Î¹B. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7397-7402.	3.3	102
380	Rev-erb-Î±: an integrator of circadian rhythms and metabolism. Journal of Applied Physiology, 2009, 107, 1972-1980.	1.2	142
381	Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptorâ€“Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 12-18.	1.1	110
382	A Review of Bile Acid Sequestrants: Potential Mechanism(s) for Glucose-Lowering Effects in Type 2 Diabetes Mellitus. Postgraduate Medicine, 2009, 121, 25-30.	0.9	45
383	Rev-erbÎ±2 mRNA Encodes a Stable Protein with a Potential Role in Circadian Clock Regulation. Molecular Endocrinology, 2009, 23, 630-639.	3.7	7
384	An Increased Flux through the Glucose 6-Phosphate Pool in Enterocytes Delays Glucose Absorption in Fxrâ€“/â€“ Mice. Journal of Biological Chemistry, 2009, 284, 10315-10323.	1.6	51
385	Rexinoid Bexarotene Modulates Triglyceride but not Cholesterol Metabolism via Gene-Specific Permissivity of the RXR/LXR Heterodimer in the Liver. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1488-1495.	1.1	63
386	Morphologic and Electroretinographic Phenotype of SR-BI Knockout Mice after a Long-Term Atherogenic Diet. , 2009, 50, 3931.		35
387	Liver X receptor modulators: Effects on lipid metabolism and potential use in the treatment of atherosclerosis. Biochemical Pharmacology, 2009, 77, 1316-1327.	2.0	92
388	Inhibition of adipocyte differentiation by RORÎ±. FEBS Letters, 2009, 583, 2031-2036.	1.3	33
389	Characterization of New PPARÎ³ Agonists: Analysis of Telmisartanâ€™s Structural Components. ChemMedChem, 2009, 4, 445-456.	1.6	38
390	Characterization of New PPARÎ³ Agonists: Benzimidazole Derivatives - the Importance of Positionâ€...2. ChemMedChem, 2009, 4, 1136-1142.	1.6	22
391	Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?. Acta Diabetologica, 2009, 46, 173-181.	1.2	22
392	Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease. Current Atherosclerosis Reports, 2009, 11, 281-288.	2.0	14
393	Effects of Microdesmis keayana alkaloids on vascular parameters of erectile dysfunction. Phytotherapy Research, 2009, 23, 892-895.	2.8	10
394	Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature, 2009, 458, 83-86.	13.7	273
395	Fenofibrate, a peroxisome proliferatorâ€“activated receptorâ€Î± agonist, exerts anticonvulsive properties. Epilepsia, 2009, 50, 943-948.	2.6	47
396	4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARÎ±/Î³ agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2683-2687.	1.0	17

#	Article	IF	Citations
397	Novel non-carboxylic acid retinoids: 1,2,4-Oxadiazol-5-one derivatives. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 489-492.	1.0	15
398	Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation. Physiological Reviews, 2009, 89, 147-191.	13.1	1,309
399	Beneficial effects of fenofibrate on plaque thrombogenicity and plaque stability in atherosclerotic rabbits. Cardiovascular Pathology, 2009, 18, 140-147.	0.7	18
400	Lipid ligand-activated transcription factors regulating lipid storage and release in human macrophages. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 486-493.	1.2	25
401	A pan-PPAR ligand induces hepatic fatty acid oxidation in PPARÎ±â^'/â^' mice possibly through PGC-1 mediated PPARÎ´ coactivation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 1076-1083.	1.2	15
402	Unlike PPARÎ³, PPARÎ± or PPARÎ²/Î´ activation does not promote human monocyte differentiation toward alternative macrophages. Biochemical and Biophysical Research Communications, 2009, 386, 459-462.	1.0	50
403	How to modulate FXR activity to treat the Metabolic Syndrome. Drug Discovery Today Disease Mechanisms, 2009, 6, e55-e64.	0.8	9
404	Tissue Factor Pathway Inhibitor-2 gene methylation is associated with low expression in carotid atherosclerotic plaques. Atherosclerosis, 2009, 204, e4-e14.	0.4	40
405	On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis, 2009, 205, 413-419.	0.4	108
406	Fenofibrate Simultaneously Induces Hepatic Fatty Acid Oxidation, Synthesis, and Elongation in Mice. Journal of Biological Chemistry, 2009, 284, 34036-34044.	1.6	141
407	Combination therapy of statins and fibrates in the management of cardiovascular risk. Current Opinion in Lipidology, 2009, 20, 505-511.	1.2	45
408	Circumventing glucocorticoid-mediated hyperinsulinemia via the activation of PPARÎ±. Cell Cycle, 2009, 8, 2311-2312.	1.3	5
409	LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice. Journal of Clinical Investigation, 2009, 119, 3830-3838.	3.9	47
410	Peroxisome Proliferator-Activated Receptor-α Activation Protects Brain Capillary Endothelial Cells from Oxygen-Glucose Deprivation-Induced Hyperpermeability in the Blood-Brain Barrier. Current Neurovascular Research, 2009, 6, 181-193.	0.4	56
411	Technologyâ€assisted learning: a longitudinal field study of knowledge category, learning effectiveness and satisfaction in language learning. Journal of Computer Assisted Learning, 2008, 24, 245-259.	3.3	87
412	Peroxisome proliferatorâ€activated receptors â€“ from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease. Journal of Internal Medicine, 2008, 263, 28-42.	2.7	39
413	The glucocorticoid receptor is a coâ€regulator of the orphan nuclear receptor Nurr1. Journal of Neurochemistry, 2008, 104, 777-789.	2.1	27
414	Modulating liver inflammation: a crucial role for cholesterol. Chemistry and Physics of Lipids, 2008, 154, S14.	1.5	0

#	Article	IF	Citations
415	Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology, 2008, 48, 474-486.	3.6	413
416	4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARÎ±/Î³ agonists. Part I: Synthesis and pharmacological evaluation. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1617-1622.	1.0	36
417	A central role for cholesterol metabolism and inflammation during the inhibition of non-alcoholic steatohepatitis with a synthetic PPARÎ± agonist. Chemistry and Physics of Lipids, 2008, 154, S56.	1.5	0
418	Association between liver X receptor Î± gene polymorphisms and risk of metabolic syndrome in French populations. International Journal of Obesity, 2008, 32, 421-428.	1.6	30
419	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. American Journal of Cardiology, 2008, 102, 1K-34K.	0.7	371
420	Revâ€erbÎ± gives a time cue to metabolism. FEBS Letters, 2008, 582, 19-25.	1.3	84
421	Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Letters, 2008, 582, 949-955.	1.3	89
422	Cross-talk Between Statins and PPARÎ± in Cardiovascular Diseases: Clinical Evidence and Basic Mechanisms. Trends in Cardiovascular Medicine, 2008, 18, 73-78.	2.3	51
423	Regulation of Bile Acid Synthesis by the Nuclear Receptor Rev-erbÎ±. Gastroenterology, 2008, 135, 689-698.e5.	0.6	175
424	Peroxisome proliferator-activated receptor Î± regulates skin inflammation and humoral response in atopic dermatitis. Journal of Allergy and Clinical Immunology, 2008, 121, 962-968.e6.	1.5	69
425	Vasoactivity, antioxidant and aphrodisiac properties of Caesalpinia benthamiana roots. Journal of Ethnopharmacology, 2008, 116, 112-119.	2.0	27
426	STATINS INCREASE EXPRESSION OF PLA2G7 IN MOUSE PERITONEAL MACROPHAGES. Atherosclerosis Supplements, 2008, 9, 201.	1.2	0
427	Apolipoprotein CIII. Circulation Research, 2008, 103, 1348-1350.	2.0	13
428	Liver-Specific Peroxisome Proliferatorâ€“Activated Receptor Î± Target Gene Regulation by the Angiotensin Type 1 Receptor Blocker Telmisartan. Diabetes, 2008, 57, 1405-1413.	0.3	74
429	Liver X Receptor Activation Induces the Uptake of Cholesteryl Esters From High Density Lipoproteins in Primary Human Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 2288-2295.	1.1	28
430	Suppression of Pro-inflammatory Adhesion Molecules by PPAR-Î´ in Human Vascular Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 315-321.	1.1	137
431	Cardiac hypertrophy is enhanced in PPARÂ-/- mice in response to chronic pressure overload. Cardiovascular Research, 2008, 78, 79-89.	1.8	116
432	Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice. Journal of Lipid Research, 2008, 49, 217-229.	2.0	59

#	Article	IF	Citations
433	PPARs/RXRs in Cardiovascular Physiology and Disease. PPAR Research, 2008, 2008, 1-1.	1.1	12
434	The nuclear receptors Rev-erbs and RORs integrate circadian rhythms and metabolism. Diabetes and Vascular Disease Research, 2008, 5, 82-88.	0.9	111
435	Regulation of Macrophage Functions by PPAR-Î±, PPAR-Î³, and LXRs in Mice and Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1050-1059.	1.1	262
436	Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells. Biochemical Journal, 2008, 410, 245-253.	1.7	49
437	The PPARÎ±/p16 ^{INK4a} Pathway Inhibits Vascular Smooth Muscle Cell Proliferation by Repressing Cell Cycleâ€“Dependent Telomerase Activation. Circulation Research, 2008, 103, 1155-1163.	2.0	61
438	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes and Vascular Disease Research, 2008, 5, 319-335.	0.9	227
439	Atheroprotective Effect of Human Apolipoprotein A5 in a Mouse Model of Mixed Dyslipidemia. Circulation Research, 2008, 103, 450-453.	2.0	33
440	Induction of CXCR2 Receptor by Peroxisome Proliferator-Activated Receptor Î³ in Human Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 932-939.	1.1	23
441	Systemic and Distal Repercussions of Liver-Specific Peroxisome Proliferator-Activated Receptor-Î± Control of the Acute-Phase Response. Endocrinology, 2008, 149, 3215-3223.	1.4	53
442	Fibrates and future PPARÎ± agonists in the treatment of cardiovascular disease. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 542-553.	3.3	141
443	The Nuclear Receptor Rev-erbÎ± Is a Liver X Receptor (LXR) Target Gene Driving a Negative Feedback Loop on Select LXR-Induced Pathways in Human Macrophages. Molecular Endocrinology, 2008, 22, 1797-1811.	3.7	54
444	Intestine-Specific Regulation of PPARÎ± Gene Transcription by Liver X Receptors. Endocrinology, 2008, 149, 5128-5135.	1.4	29
445	Phosphorylation of Farnesoid X Receptor by Protein Kinase C Promotes Its Transcriptional Activity. Molecular Endocrinology, 2008, 22, 2433-2447.	3.7	66
446	ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver. Journal of Clinical Investigation, 2008, 118, 956-64.	3.9	158
447	Liver X Receptor Activation Potentiates the Lipopolysaccharide Response in Human Macrophages. Circulation Research, 2007, 101, 40-49.	2.0	117
448	Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 145-156.	2.9	136
449	IAP Survivin Regulates Atherosclerotic Macrophage Survival. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 901-907.	1.1	34
450	The PPARÎ± Activator Fenofibrate Slows Down the Progression of the Left Ventricular Dysfunction in Porcine Tachycardia-Induced Cardiomyopathy. Journal of Cardiovascular Pharmacology, 2007, 49, 408-415.	0.8	61

#	Article	IF	Citations
451	The farnesoid X receptor induces fetuin-B gene expression in human hepatocytes. Biochemical Journal, 2007, 407, 461-469.	1.7	17
452	Peroxisome Proliferator-Activated Receptor Î³ and Adipose Tissueâ€"Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 386-395.	1.8	423
453	Measuring biomarkers to assess the therapeutic effects of PPAR agonists?. Pharmacogenomics, 2007, 8, 1567-1580.	0.6	4
454	Inhibition of progesterone production in human luteinized granulosa cells treated with LXR agonists. Molecular Human Reproduction, 2007, 13, 373-379.	1.3	37
455	Retinoid-related orphan receptor Â regulates several genes that control metabolism in skeletal muscle cells: links to modulation of reactive oxygen species production. Journal of Molecular Endocrinology, 2007, 39, 29-44.	1.1	40
456	Inter-subject differences in constitutive expression levels of the clock gene in man. Diabetes and Vascular Disease Research, 2007, 4, 39-43.	0.9	14
457	Peroxisome Proliferator-Activated Receptors Mediate Pleiotropic Actions of Statins. Circulation Research, 2007, 100, 1394-1395.	2.0	33
458	S 26948: a New Specific Peroxisome Proliferator Activated Receptor Â Modulator With Potent Antidiabetes and Antiatherogenic Effects. Diabetes, 2007, 56, 2797-2808.	0.3	50
459	PPAR Agonists and the Metabolic Syndrome. Therapie, 2007, 62, 319-326.	0.6	37
460	Transcriptional regulation of macrophage cholesterol trafficking by PPARÎ± and LXR. Biochemical Society Transactions, 2007, 35, 165-165.	1.6	0
461	Bile acids, farnesoid X receptor, atherosclerosis and metabolic control. Current Opinion in Lipidology, 2007, 18, 289-297.	1.2	53
462	The orphan nuclear receptor Rev-erbÎ±: a transcriptional link between circadian rhythmicity and cardiometabolic disease. Current Opinion in Lipidology, 2007, 18, 141-146.	1.2	31
463	FXR: a promising target for the metabolic syndrome?. Trends in Pharmacological Sciences, 2007, 28, 236-243.	4.0	136
464	Safety issues and prospects for future generations of PPAR modulators. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2007, 1771, 1065-1081.	1.2	255
465	PPARÎ´, but not PPARÎ±, activates PGC-1Î± gene transcription in muscle. Biochemical and Biophysical Research Communications, 2007, 354, 1021-1027.	1.0	110
466	IP receptor-dependent activation of PPARÎ³ by stable prostacyclin analogues. Biochemical and Biophysical Research Communications, 2007, 360, 821-827.	1.0	59
467	PPARÎ³ Activation Primes Human Monocytes into Alternative M2 Macrophages with Anti-inflammatory Properties. Cell Metabolism, 2007, 6, 137-143.	7.2	1,125
468	The core component of the mammalian SWI/SNF complex SMARCD3/BAF60c is a coactivator for the nuclear retinoic acid receptor. Molecular and Cellular Endocrinology, 2007, 270, 23-32.	1.6	41

#	Article	IF	Citations
469	Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in atherosclerotic plaques. Atherosclerosis, 2007, 195, e117-e125.	0.4	19
470	FXRâ€deficiency confers increased susceptibility to torpor. FEBS Letters, 2007, 581, 5191-5198.	1.3	30
471	PPARÂ Agonists Suppress Osteopontin Expression in Macrophages and Decrease Plasma Levels in Patients With Type 2 Diabetes. Diabetes, 2007, 56, 1662-1670.	0.3	65
472	Bile???Acid???Sequestrants???and???the???Treatment of Type??2??Diabetes??Mellitus. Drugs, 2007, 67, 1383-1392.	4.9	149
473	PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Practice and Research in Clinical Endocrinology and Metabolism, 2007, 21, 687-710.	2.2	170
474	Genetically-engineered animals as research models for atherosclerosis : their use for the characterization of PPAR agonists in the treatment of cardiometabolic disorders. Frontiers in Bioscience - Landmark, 2007, 12, 4132.	3.0	10
475	Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor Î± agonists. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4689-4693.	1.0	76
476	Glitazones in the treatment of cardiovascular risk factors. Fundamental and Clinical Pharmacology, 2007, 21, 7-13.	1.0	3
477	Metformin and pioglitazone: effectively treating insulin resistance. Current Medical Research and Opinion, 2006, 22, S27-S37.	0.9	44
478	Overview of Nomenclature of Nuclear Receptors. Pharmacological Reviews, 2006, 58, 685-704.	7.1	540
479	Mo-W6:1 Metabolic and vascular control by lipid-sensing nuclear receptors: Role of the peroxisome proliferator-activated receptor-alpha as a mediator of the pleiotropic effects of statins. Atherosclerosis Supplements, 2006, 7, 20-21.	1.2	0
480	Th-W60:3 Acute anti-inflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the PKC signalling pathway. Atherosclerosis Supplements, 2006, 7, 487.	1.2	1
481	Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. Journal of Endocrinology, 2006, 189, 199-209.	1.2	173
482	Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease. Journal of the American College of Cardiology, 2006, 48, A24-A32.	1.2	35
483	Niemannâ€“Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochemical and Biophysical Research Communications, 2006, 340, 1259-1263.	1.0	156
484	PPARÎ± and PPARÎ³ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Current Opinion in Pharmacology, 2006, 6, 606-614.	1.7	176
485	Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. Journal of Hepatology, 2006, 44, 732-741.	1.8	213
486	The expanding role of the bile acid receptor FXR in the small intestine. Journal of Hepatology, 2006, 44, 1213-1215.	1.8	16

#	Article	IF	Citations
487	Transcriptional regulation of macrophage cholesterol trafficking by PPARÎ± and LXR. Biochemical Society Transactions, 2006, 34, 1128-1131.	1.6	21
488	Sorting out the roles of PPARÂ in energy metabolism and vascular homeostasis. Journal of Clinical Investigation, 2006, 116, 571-580.	3.9	779
489	PPARs in Atherosclerosis. , 2006, , 159-179.		1
490	Human retinoic acid receptor-related orphan receptor ?1 overexpression protects neurones against oxidative stress-induced apoptosis. Journal of Neurochemistry, 2006, 96, 1778-1789.	2.1	84
491	When the Clock stops ticking, metabolic syndrome explodes. Nature Medicine, 2006, 12, 54-55.	15.2	144
492	Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARÎ³ agonists. Bioorganic and Medicinal Chemistry, 2006, 14, 7377-7391.	1.4	18
493	Studies towards the conception of new selective PPARÎ²/Î´ ligands. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4528-4532.	1.0	17
494	Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis. Expert Opinion on Emerging Drugs, 2006, 11, 379-401.	1.0	91
495	The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia, 2006, 49, 527-537.	2.9	64
496	[4-(2H-1,2,3-Benzotriazol-2-yl)phenoxy]alkanoic Acids as Agonists of Peroxisome Proliferator-Activated Receptors (PPARs). Chemistry and Biodiversity, 2006, 3, 385-395.	1.0	9
497	The liver X-receptor alpha controls hepatic expression of the human bile acid-glucuronidating UGT1A3 enzyme in human cells and transgenic mice. Hepatology, 2006, 44, 368-378.	3.6	64
498	Paullinia pinnata Extracts Rich in Polyphenols Promote Vascular Relaxation via Endothelium-dependent Mechanisms. Journal of Cardiovascular Pharmacology, 2006, 47, 599-608.	0.8	44
499	FXR: More than a Bile Acid Receptor?. Endocrinology, 2006, 147, 4022-4024.	1.4	8
500	Effect of Rosiglitazone Treatment on Plaque Inflammation and Collagen Content in Nondiabetic Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 845-850.	1.1	61
501	Peroxisome Proliferator-Activated Receptor Â Improves Pancreatic Adaptation to Insulin Resistance in Obese Mice and Reduces Lipotoxicity in Human Islets. Diabetes, 2006, 55, 1605-1613.	0.3	100
502	PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochemical Society Transactions, 2006, 34, 1341-1346.	1.6	263
503	Cholesterol 7Î±-Hydroxylase Deficiency in Mice on an APOE*3-Leiden Background Increases Hepatic ABCA1 mRNA Expression and HDL-Cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2724-2730.	1.1	8
504	Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPARâ€“Î± Activators. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 977-986.	1.1	154

#	Article	IF	Citations
505	The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice. Journal of Biological Chemistry, 2006, 281, 11039-11049.	1.6	463
506	Acute Antiinflammatory Properties of Statins Involve Peroxisome Proliferatorâ€“Activated Receptor-Î± via Inhibition of the Protein Kinase C Signaling Pathway. Circulation Research, 2006, 98, 361-369.	2.0	157
507	TReP-132 Is a Novel Progesterone Receptor Coactivator Required for the Inhibition of Breast Cancer Cell Growth and Enhancement of Differentiation by Progesterone. Molecular and Cellular Biology, 2006, 26, 7632-7644.	1.1	29
508	Transcription Factor TCF7L2 Genetic Study in the French Population: Expression in Human Â-Cells and Adipose Tissue and Strong Association With Type 2 Diabetes. Diabetes, 2006, 55, 2903-2908.	0.3	300
509	Both Hepatic and Extrahepatic ABCA1 Have Discrete and Essential Functions in the Maintenance of Plasma High-Density Lipoprotein Cholesterol Levels In Vivo. Circulation, 2006, 114, 1301-1309.	1.6	80
510	International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors. Pharmacological Reviews, 2006, 58, 726-741.	7.1	869
511	Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c. Journal of Biological Chemistry, 2006, 281, 6211-6218.	1.6	260
512	The RXR Agonist Bexarotene Improves Cholesterol Homeostasis and Inhibits Atherosclerosis Progression in a Mouse Model of Mixed Dyslipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2731-2737.	1.1	69
513	Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. Journal of Clinical Investigation, 2006, 116, 1052-1062.	3.9	447
514	Molecular Characterization of New Selective Peroxisome Proliferator-Activated Receptor Â Modulators With Angiotensin Receptor Blocking Activity. Diabetes, 2005, 54, 3442-3452.	0.3	270
515	The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes, Obesity and Metabolism, 2005, 7, 65-72.	2.2	198
516	Pro-inflammatory properties for thiazolidinediones. Biochemical Pharmacology, 2005, 69, 255-265.	2.0	23
517	Pleiotropic effects of fibrates. Current Atherosclerosis Reports, 2005, 7, 396-401.	2.0	39
518	The Farnesoid X Receptor Modulates Hepatic Carbohydrate Metabolism during the Fasting-Refeeding Transition. Journal of Biological Chemistry, 2005, 280, 29971-29979.	1.6	186
519	Reduced cholesterol absorption upon PPARÎ´ activation coincides with decreased intestinal expression of NPC1L1. Journal of Lipid Research, 2005, 46, 526-534.	2.0	161
520	Insulin-Mediated Down-Regulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway: Role of Upstream Stimulatory Factor. Molecular and Cellular Biology, 2005, 25, 1537-1548.	1.1	88
521	Hepatic Expression of the UGT1A9 Gene Is Governed by Hepatocyte Nuclear Factor 4Î±. Molecular Pharmacology, 2005, 67, 241-249.	1.0	61
522	The Farnesoid X Receptor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2020-2030.	1.1	425

#	Article	IF	Citations
523	Peroxisome proliferator-activated receptor Î± controls cellular cholesterol trafficking in macrophages. Journal of Lipid Research, 2005, 46, 2717-2725.	2.0	60
524	Complete functional rescue of the ABCA1â^'/â^' mouse by human BAC transgenesis. Journal of Lipid Research, 2005, 46, 1113-1123.	2.0	11
525	A fully dissociated compound of plant origin for inflammatory gene repression. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15827-15832.	3.3	245
526	Farnesoid X Receptor: A New Player in Glucose Metabolism?. Endocrinology, 2005, 146, 981-983.	1.4	38
527	PPARÎ±, but not PPARÎ³, Activators Decrease Macrophage-Laden Atherosclerotic Lesions in a Nondiabetic Mouse Model of Mixed Dyslipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1897-1902.	1.1	70
528	TReP-132 Controls Cell Proliferation by Regulating the Expression of the Cyclin-Dependent Kinase Inhibitors p21WAF1/Cip1 and p27Kip1. Molecular and Cellular Biology, 2005, 25, 4335-4348.	1.1	25
529	The Gene Encoding Acyl-CoA-binding Protein Is Subject to Metabolic Regulation by Both Sterol Regulatory Element-binding Protein and Peroxisome Proliferator-activated Receptor Î± in Hepatocytes. Journal of Biological Chemistry, 2005, 280, 5258-5266.	1.6	44
530	Review: Vascular protective effects of peroxisome proliferator-activated receptor agonists. British Journal of Diabetes and Vascular Disease, 2005, 5, 126-132.	0.6	2
531	Liver X Receptor Activation Controls Intracellular Cholesterol Trafficking and Esterification in Human Macrophages. Circulation Research, 2005, 97, 682-689.	2.0	108
532	The Gene Encoding Fibrinogen-Î² Is a Target for Retinoic Acid Receptor-Related Orphan Receptor Î±. Molecular Endocrinology, 2005, 19, 2517-2526.	3.7	12
533	W15-IS-001 PPARS as targets for anti-atherosclerotic therapies. Atherosclerosis Supplements, 2005, 6, 95.	1.2	0
534	W15-IS-002 Role of farnesoid X receptor (FXR) in control of plasma lipid levels. Atherosclerosis Supplements, 2005, 6, 95-96.	1.2	0
535	W15-O-003 Atheroprotective effect of the rexinoid targretin in a murine model of atherosclerosis. Atherosclerosis Supplements, 2005, 6, 96.	1.2	1
536	Therapeutical effects of PPAR agonists assessed by biomarker modulation. Biomarkers, 2005, 10, 30-36.	0.9	9
537	Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator-Activated Receptor Î± Modulation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 585-591.	1.1	116
538	PPARÎ³ and atherosclerosis. Current Medical Research and Opinion, 2005, 21, S13-S20.	0.9	68
539	Transcriptional Regulation of Apolipoprotein A5 Gene Expression by the Nuclear Receptor RORÎ±. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1186-1192.	1.1	50
540	Fenofibrate reverses the decline in HDL cholesterol in mice overexpressing human phospholipid transfer protein. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1738, 48-53.	1.2	9

#	Article	IF	Citations
541	Fluid retention mediated by renal PPARÎ³. Cell Metabolism, 2005, 2, 77-78.	7.2	47
542	Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy. Current Opinion in Pharmacology, 2005, 5, 177-183.	1.7	84
543	Potential regulatory role of the farnesoid X receptor in the metabolic syndrome. Biochimie, 2005, 87, 93-98.	1.3	32
544	The role of the orphan nuclear receptor Rev-ErbÎ± in adipocyte differentiation and function. Biochimie, 2005, 87, 21-25.	1.3	48
545	Pancreatic islet response to hyperglycemia is dependent on peroxisome proliferator-activated receptor alpha (PPARÎ±). FEBS Letters, 2005, 579, 2284-2288.	1.3	21
546	Transient impairment of the adaptive response to fasting in FXR-deficient mice. FEBS Letters, 2005, 579, 4076-4080.	1.3	72
547	Progesterone inhibits human breast cancer cell growth through transcriptional upregulation of the cyclin-dependent kinase inhibitor p27Kip1gene. FEBS Letters, 2005, 579, 5535-5541.	1.3	30
548	Peroxisome Proliferator-Activated Receptor Î²/Î´: A novel target for the reduction of atherosclerosis. Drug Discovery Today: Therapeutic Strategies, 2005, 2, 237-243.	0.5	7
549	Therapeutic Roles of Peroxisome Proliferator-Activated Receptor Agonists. Diabetes, 2005, 54, 2460-2470.	0.3	575
550	Synthesis, Biological Evaluation, and Molecular Modeling Investigation of New Chiral Fibrates with PPARÎ± and PPARÎ³ Agonist Activity. Journal of Medicinal Chemistry, 2005, 48, 5509-5519.	2.9	52
551	PPARÎ± inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. Journal of Clinical Investigation, 2005, 115, 3228-3238.	3.9	145
552	PPARÎ± deficiency does not modify age dependency but prevents high fat diet increase in plasma PAI-1 as well as insulin resistance. Thrombosis and Haemostasis, 2004, 91, 1051-1052.	1.8	4
553	Ala12Ala Genotype of the Peroxisome Proliferator-Activated Receptor Î³2 Protects against Atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4238-4242.	1.8	58
554	Peroxisome Proliferator-Activated Receptors and Atherogenesis. Circulation Research, 2004, 94, 1168-1178.	2.0	471
555	The Protein Kinase C Signaling Pathway Regulates a Molecular Switch between Transactivation and Transrepression Activity of the Peroxisome Proliferator-Activated Receptor Î±. Molecular Endocrinology, 2004, 18, 1906-1918.	3.7	97
556	The farnesoid X receptor: a novel drug target?. Expert Opinion on Investigational Drugs, 2004, 13, 1135-1148.	1.9	39
557	Cholesteryl ester transfer protein modulates the effect of liver X receptor agonists on cholesterol transport and excretion in the mouse. Journal of Lipid Research, 2004, 45, 543-550.	2.0	44
558	Peroxisome Proliferatorâ€“Activated Receptor Î± Induces NADPH Oxidase Activity in Macrophages, Leading to the Generation of LDL with PPAR-Î± Activation Properties. Circulation Research, 2004, 95, 1174-1182.	2.0	108

#	Article	IF	Citations
559	Regulation of Endothelial Nitric Oxide Synthase by PPAR Agonists: Molecular and Clinical Perspectives. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 619-621.	1.1	12
560	Farnesoid X receptor represses hepatic lipase gene expression. Journal of Lipid Research, 2004, 45, 2110-2115.	2.0	43
561	PPARÎ± Activators Inhibit Vascular Endothelial Growth Factor Receptor-2 Expression by Repressing Sp1-Dependent DNA Binding and Transactivation. Circulation Research, 2004, 94, 324-332.	2.0	105
562	Statin Induction of Liver Fatty Acid-Binding Protein (L-FABP) Gene Expression Is Peroxisome Proliferator-activated Receptor-Î±-dependent. Journal of Biological Chemistry, 2004, 279, 45512-45518.	1.6	84
563	The transcriptional regulating protein of 132 kDa (TReP-132) differentially influences steroidogenic pathways in human adrenal NCI-H295 cells. Journal of Molecular Endocrinology, 2004, 32, 557-569.	1.1	10
564	Hepatic de Novo Synthesis of Glucose 6-Phosphate Is Not Affected in Peroxisome Proliferator-activated Receptor Î±-Deficient Mice but Is Preferentially Directed toward Hepatic Glycogen Stores after a Short Term Fast. Journal of Biological Chemistry, 2004, 279, 8930-8937.	1.6	38
565	Glucose Regulates the Expression of the Farnesoid X Receptor in Liver. Diabetes, 2004, 53, 890-898.	0.3	226
566	Metabolic syndrome without obesity: Hepatic overexpression of 11Â-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 7088-7093.	3.3	399
567	Estrogen-Related Receptor Î± Directs Peroxisome Proliferator-Activated Receptor Î± Signaling in the Transcriptional Control of Energy Metabolism in Cardiac and Skeletal Muscle. Molecular and Cellular Biology, 2004, 24, 9079-9091.	1.1	436
568	Global Suppression of IL-6-induced Acute Phase Response Gene Expression after Chronic in Vivo Treatment with the Peroxisome Proliferator-activated Receptor-Î± Activator Fenofibrate. Journal of Biological Chemistry, 2004, 279, 16154-16160.	1.6	182
569	Novel Adipose Tissue-Mediated Resistance to Diet-Induced Visceral Obesity in 11Â-Hydroxysteroid Dehydrogenase Type 1-Deficient Mice. Diabetes, 2004, 53, 931-938.	0.3	476
570	Inflammation, dyslipidaemia, diabetes and PPARs: pharmacological interest of dual PPARÎ± and PPARÎ³ agonists. International Journal of Clinical Practice, 2004, 58, 22-29.	0.8	35
571	The Farnesoid X Receptor (FXR) as Modulator of Bile Acid Metabolism. Reviews in Endocrine and Metabolic Disorders, 2004, 5, 319-326.	2.6	58
572	Different ways to regulate the PPAR$alpha; stability. Biochemical and Biophysical Research Communications, 2004, 319, 663-663.	1.0	0
573	The farnesoid X receptor induces very low density lipoprotein receptor gene expression. FEBS Letters, 2004, 566, 173-177.	1.3	91
574	Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARÎ±, PPARÎ³, and LXR. Biochemical and Biophysical Research Communications, 2004, 314, 151-158.	1.0	239
575	Different ways to regulate the PPARÎ± stability. Biochemical and Biophysical Research Communications, 2004, 319, 663-670.	1.0	33
576	Genomic and non-genomic interactions of PPARÎ± with xenobiotic-metabolizing enzymes. Trends in Endocrinology and Metabolism, 2004, 15, 324-330.	3.1	33

#	Article	IF	Citations
577	PPARÎ± controlling HDL metabolism and atherosclerosis. International Congress Series, 2004, 1262, 215-219.	0.2	0
578	Fenofibrate Increases Homocystinemia Through a PPARÎ±-Mediated Mechanism. Journal of Cardiovascular Pharmacology, 2004, 43, 452-453.	0.8	30
579	Lesion Progression in apoE-Deficient Mice: Implication of Chemokines and Effect of the AT1 Angiotensin II Receptor Antagonist Irbesartan. Journal of Cardiovascular Pharmacology, 2004, 43, 191-199.	0.8	20
580	Inhibition of cytokine production by the herbicide atrazine. Biochemical Pharmacology, 2003, 65, 303-308.	2.0	18
581	Expression and Localization of Peroxisome Proliferator-Activated Receptors and Nuclear Factor ÎºB in Normal and Lesional Psoriatic Skin. Journal of Investigative Dermatology, 2003, 121, 1104-1117.	0.3	105
582	Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications. International Journal of Obesity, 2003, 27, S41-S45.	1.6	90
583	Induction of hepatic ABC transporter expression is part of the PPARÎ±â€“mediated fasting response in the mouse. Gastroenterology, 2003, 124, 160-171.	0.6	79
584	A Paradigm for Gene Regulation: Inflammation, NF-ÎºB and PPAR. Advances in Experimental Medicine and Biology, 2003, 544, 181-196.	0.8	199
585	FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology, 2003, 124, 1926-1940.	0.6	176
586	Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology, 2003, 125, 544-555.	0.6	235
587	Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis. Trends in Pharmacological Sciences, 2003, 24, 530-534.	4.0	26
588	Peroxisome proliferator-activator receptor-Î± activator (PPAR-Î±) dose not inhibit the activation of human hepatic stellate cells by IL-1Î². Journal of Hepatology, 2003, 38, 82.	1.8	0
589	Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2003, 1631, 107-118.	1.2	80
590	Regulation of the scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2003, 1631, 218-228.	1.2	27
591	Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. Journal of Steroid Biochemistry and Molecular Biology, 2003, 85, 267-273.	1.2	262
592	Expression and Functional Role of Peroxisome Proliferator-Activated Receptor-Î³ in Ovarian Folliculogenesis in the Sheep1. Biology of Reproduction, 2003, 69, 1665-1674.	1.2	83
593	Peroxisome Proliferatorâ€“activated Receptors Î± and Î³ Down-regulate Allergic Inflammation and Eosinophil Activation. Journal of Experimental Medicine, 2003, 198, 411-421.	4.2	239
594	Peroxisome Proliferator-Activated Receptor (PPAR) Î± and PPARÎ²/Î´, but not PPARÎ³, Modulate the Expression of Genes Involved in Cardiac Lipid Metabolism. Circulation Research, 2003, 92, 518-524.	2.0	389

#	Article	IF	Citations
595	Peroxisome Proliferator-Activated Receptor Î± Reduces Cholesterol Esterification in Macrophages. Circulation Research, 2003, 92, 212-217.	2.0	107
596	Peroxisome Proliferator-activated Receptor Î± Induces Hepatic Expression of the Human Bile Acid Glucuronidating UDP-glucuronosyltransferase 2B4 Enzyme. Journal of Biological Chemistry, 2003, 278, 32852-32860.	1.6	123
597	Bile Acids Induce the Expression of the Human Peroxisome Proliferator-Activated Receptor Î± Gene via Activation of the Farnesoid X Receptor. Molecular Endocrinology, 2003, 17, 259-272.	3.7	391
598	The Orphan Nuclear Receptor Rev-ErbÎ± Is a Peroxisome Proliferator-activated Receptor (PPAR) Î³ Target Gene and Promotes PPARÎ³-induced Adipocyte Differentiation. Journal of Biological Chemistry, 2003, 278, 37672-37680.	1.6	215
599	The Two Variants of Oxysterol Binding Protein-related Protein-1 Display Different Tissue Expression Patterns, Have Different Intracellular Localization, and Are Functionally Distinct. Molecular Biology of the Cell, 2003, 14, 903-915.	0.9	100
600	The UDP-glucuronosyltransferase 1A9 Enzyme Is a Peroxisome Proliferator-activated Receptor Î± and Î³ Target Gene. Journal of Biological Chemistry, 2003, 278, 13975-13983.	1.6	113
601	Peroxisome Proliferator-Activated Receptor Î³ Inhibits the Migration of Dendritic Cells: Consequences for the Immune Response. Journal of Immunology, 2003, 170, 5295-5301.	0.4	85
602	Apolipoprotein A5, a Crucial Determinant of Plasma Triglyceride Levels, Is Highly Responsive to Peroxisome Proliferator-activated Receptor Î± Activators. Journal of Biological Chemistry, 2003, 278, 17982-17985.	1.6	186
603	Fibrates Down-regulate Hepatic Scavenger Receptor Class B Type I Protein Expression in Mice. Journal of Biological Chemistry, 2003, 278, 7884-7890.	1.6	115
604	PPARs and atherosclerosis. Advances in Molecular and Cell Biology, 2003, 33, 543-560.	0.1	0
605	Rupture of the Atherosclerotic Plaque. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 535-542.	1.1	107
606	Liver X receptors: new players in atherogenesis?. Current Opinion in Lipidology, 2003, 14, 137-143.	1.2	18
607	Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function. Current Opinion in Lipidology, 2003, 14, 459-468.	1.2	83
608	Fibrates down-regulate IL-1â€“stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFÎºBâ€“C/EBP-Î² complex formation. Blood, 2003, 101, 545-551.	0.6	211
609	Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochemical Journal, 2003, 369, 539-547.	1.7	150
610	Potential roles of ROR-Î± in cardiovascular endocrinology. Nuclear Receptor Signaling, 2003, 1, nrs.01011.	1.0	8
611	Different short- and long-term effects of resveratrol on nuclear factor-ÎºB phosphorylation and nuclear appearance in human endothelial cells. American Journal of Clinical Nutrition, 2003, 77, 1220-1228.	2.2	73
612	Ppar-Alpha in Lipid and Lipoprotein Metabolism, Vascular Inflammation and Atherosclerosis. Progress in Experimental Cardiology, 2003, , 3-16.	0.0	3

#	Article	IF	Citations
613	Peroxisome Proliferator-Activated Receptor-Î± Activation as a Mechanism of Preventive Neuroprotection Induced by Chronic Fenofibrate Treatment. Journal of Neuroscience, 2003, 23, 6264-6271.	1.7	212
614	Pleiotropic Actions of Peroxisome Proliferatorâ€“Activated Receptors in Lipid Metabolism and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 717-726.	1.1	388
615	Transcriptional Regulation of Human Rev-erbÎ± Gene Expression by the Orphan Nuclear Receptor Retinoic Acid-related Orphan Receptor Î±. Journal of Biological Chemistry, 2002, 277, 49275-49281.	1.6	60
616	Efficient Gene Regulation by PPARÎ³ and Thiazolidinediones in Skeletal Muscle and Heart. Molecular Therapy, 2002, 6, 265-271.	3.7	5
617	Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-Â, Inhibits the Jun NH2-Terminal Kinase/Activating Protein 1 Pathway and Protects the Heart From Ischemia/Reperfusion Injury. Diabetes, 2002, 51, 1507-1514.	0.3	173
618	Peroxisome Proliferator-Activated Receptor Î± Gene Variants Influence Progression of Coronary Atherosclerosis and Risk of Coronary Artery Disease. Circulation, 2002, 105, 1440-1445.	1.6	136
619	Peroxisome Proliferatorâ€“Activated Receptor Î± Gene Regulates Left Ventricular Growth in Response to Exercise and Hypertension. Circulation, 2002, 105, 950-955.	1.6	149
620	Peroxisome Proliferator-activated Receptor Î± (PPARÎ±) Turnover by the Ubiquitin-Proteasome System Controls the Ligand-induced Expression Level of Its Target Genes. Journal of Biological Chemistry, 2002, 277, 37254-37259.	1.6	121
621	Peroxisome Proliferatorâ€“activated Receptor Activators Inhibit Oxidized Low-density Lipoproteinâ€“induced Endothelin-1 Secretion in Endothelial Cells. Journal of Cardiovascular Pharmacology, 2002, 40, 822-831.	0.8	83
622	FUNCTION OF THE TRANSCRIPTIONAL REGULATING PROTEIN OF 132 kDa (TReP-132) ON HUMAN P450scc GENE EXPRESSION. Endocrine Research, 2002, 28, 559-574.	0.6	10
623	DNA Binding-Independent Induction of IÎºBÎ± Gene Transcription by PPARÎ±. Molecular Endocrinology, 2002, 16, 1029-1039.	3.7	95
624	PPARÎ± Inhibits TGF-Î²â€“Induced Î² 5 Integrin Transcription in Vascular Smooth Muscle Cells by Interacting With Smad4. Circulation Research, 2002, 91, e35-44.	2.0	62
625	Identification of Rev-erbÎ± as a physiological repressor of apoC-III gene transcription. Journal of Lipid Research, 2002, 43, 2172-2179.	2.0	159
626	The Transcriptional Regulating Protein of 132 kDa (TReP-132) Enhances P450scc Gene Transcription through Interaction with Steroidogenic Factor-1 in Human Adrenal Cells. Journal of Biological Chemistry, 2002, 277, 39144-39155.	1.6	52
627	Human Sterol 27-Hydroxylase (CYP27) Overexpressor Transgenic Mouse Model. Journal of Biological Chemistry, 2002, 277, 34036-34041.	1.6	65
628	RÃ1es des â€œPeroxisome Proliferator-Activated Receptorsâ€•(PPARs) dans la rÃ©gulation du mÃ©tabolisme des lipides et le contrÃ1e de lâ€™inflammation. SociÃ©tÃ© De Biologie Journal, 2002, 196, 47-52.	0.3	35
629	HMG-CoA reductase inhibition and PPAR-alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells. Clinical Science, 2002, 103, 81S-83S.	1.8	10
630	Dietary trans-10,cis-12 conjugated linoleic acid induces hyperinsulinemia and fatty liver in the mouse. Journal of Lipid Research, 2002, 43, 1400-1409.	2.0	308

#	Article	IF	Citations
631	Characterization of the Human PPARÎ± Promoter: Identification of a Functional Nuclear Receptor Response Element. Molecular Endocrinology, 2002, 16, 1013-1028.	3.7	144
632	Reduction of Atherosclerosis by the Peroxisome Proliferator-activated Receptor Î± Agonist Fenofibrate in Mice. Journal of Biological Chemistry, 2002, 277, 48051-48057.	1.6	174
633	Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages. FEBS Letters, 2002, 512, 85-90.	1.3	69
634	The role of PPARs in atherosclerosis. Trends in Molecular Medicine, 2002, 8, 422-430.	3.5	228
635	Age-related phenotypes in the staggerer mouse expand the RORÎ± nuclear receptor's role beyond the cerebellum. Molecular and Cellular Endocrinology, 2002, 186, 1-5.	1.6	68
636	The clinical significance of PPARÎ± and Î³ agonism. British Journal of Diabetes and Vascular Disease, 2002, 2, S28-S31.	0.6	6
637	Extracorporal albumin dialysis (MARS) improves cholestasis and normalizes low apo A-I levels in a patient with benign recurrent intrahepatic cholestasis (BRIC). Liver, 2002, 22, 72-75.	0.1	40
638	A cholesterol tether. Nature, 2002, 417, 699-701.	13.7	28
639	PPARs: Transcription Factors Controlling Lipid and Lipoprotein Metabolism. Annals of the New York Academy of Sciences, 2002, 967, 7-18.	1.8	148
640	Role of PPARs in Inflammation, Atherosclerosis, and Thrombosis. Medical Science Symposia Series, 2002, , 25-34.	0.0	1
641	Tetradecylthioacetic acid prevents high fat diet induced adiposity and insulin resistance. Journal of Lipid Research, 2002, 43, 742-750.	2.0	45
642	Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. Journal of Clinical Investigation, 2002, 109, 961-971.	3.9	244
643	Increased ABCA1 activity protects against atherosclerosis. Journal of Clinical Investigation, 2002, 110, 35-42.	3.9	216
644	Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. Journal of Clinical Investigation, 2002, 109, 961-971.	3.9	110
645	Increased ABCA1 activity protects against atherosclerosis. Journal of Clinical Investigation, 2002, 110, 35-42.	3.9	121
646	DNA Binding-Independent Induction of IÂBÂ Gene Transcription by PPARÂ. Molecular Endocrinology, 2002, 16, 1029-1039.	3.7	59
647	PPARÎ±, Lipoprotein Metabolism, Metabolic Diseases, and Atherosclerosis. Medical Science Symposia Series, 2002, , 63-79.	0.0	0
648	Tetradecylthioacetic acid prevents high fat diet induced adiposity and insulin resistance. Journal of Lipid Research, 2002, 43, 742-50.	2.0	42

#	Article	IF	Citations
649	PPARs in Inflammation, Atherosclerosis and Thrombosis. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 187-194.	3.1	40
650	Ppars, metabolic disease and atherosclerosis. Pharmacological Research, 2001, 44, 345-352.	3.1	110
651	Regulation of lipid and lipoprotein metabolism by retinoids. Journal of the American Academy of Dermatology, 2001, 45, S158-S167.	0.6	66
652	New roles for PPARs in cholesterol homeostasis. Trends in Pharmacological Sciences, 2001, 22, 444.	4.0	2
653	Expression of human apolipoprotein A-I/C-III/A-IV gene cluster in mice reduces atherogenesis in response to a high fat-high cholesterol diet. FEBS Letters, 2001, 502, 16-20.	1.3	16
654	Angiotensin AT1 Receptor Antagonist Irbesartan Decreases Lesion Size, Chemokine Expression, and Macrophage Accumulation in Apolipoprotein E-Deficient Mice. Journal of Cardiovascular Pharmacology, 2001, 38, 395-405.	0.8	91
655	Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Current Opinion in Lipidology, 2001, 12, 245-254.	1.2	182
656	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 187-194.	1.5	66
657	Oxidized low-density lipoprotein and peroxisome-proliferator-activated receptor Î± down-regulate platelet-activating-factor receptor expression in human macrophages. Biochemical Journal, 2001, 354, 225.	1.7	23
658	Oxidized low-density lipoprotein and peroxisome-proliferator-activated receptor Î± down-regulate platelet-activating-factor receptor expression in human macrophages. Biochemical Journal, 2001, 354, 225-232.	1.7	27
659	The role of fibric acids in atherosclerosis. Current Atherosclerosis Reports, 2001, 3, 83-92.	2.0	164
660	Peroxisome proliferator-activated receptor Î³ activators affect the maturation of human monocyte-derived dendritic cells. European Journal of Immunology, 2001, 31, 2857-2865.	1.6	212
661	Schistosoma mansoni induces the synthesis of IL-6 in pulmonary microvascular endothelial cells: role of IL-6 in the control of lung eosinophilia during infection. European Journal of Immunology, 2001, 31, 2751-2761.	1.6	33
662	The orphan nuclear receptor RORÎ± is a negative regulator of the inflammatory response. EMBO Reports, 2001, 2, 42-48.	2.0	259
663	PPAR-Î± and PPAR-Î³ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Medicine, 2001, 7, 53-58.	15.2	1,075
664	Lack of toxic effects of F 12511, a novel potent inhibitor of acyl-coenzyme A: cholesterol O-acyltransferase, on human adrenocortical cells in culture11Abbreviations: ACAT, acyl-coenzyme A: cholesterol O-acyltransferase; F 12511, (S)-2â€²,3â€²,5â€²-trimethyl-4â€²-hydroxy-Î±-dodecylthio-phenylacetanilide; DMEM, Dulbeccoâ€™s modified Eagle medium; FBS, fetal bovine serum; LDL, low-density lipoprotein; HDL, high-density lipoprotein; SR-BI, scavenger receptor class B, type I; P450scc, cytochrome P450 cholesterol side-chai. Biochemical Pharmacology, 2001, 61, 387-398.	2.0	18
665	Negative Regulation of Human Fibrinogen Gene Expression by Peroxisome Proliferator-activated Receptor Î± Agonists via Inhibition of CCAAT Box/Enhancer-binding Protein Î². Journal of Biological Chemistry, 2001, 276, 33471-33477.	1.6	140
666	Fibrates Suppress Bile Acid Synthesis via Peroxisome Proliferatorâ€“Activated Receptor-Î±â€“Mediated Downregulation of Cholesterol 7Î±-Hydroxylase and Sterol 27-Hydroxylase Expression. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1840-1845.	1.1	185

#	Article	IF	Citations
667	Peroxisome proliferator-activated receptors in inflammation control. Journal of Endocrinology, 2001, 169, 453-459.	1.2	697
668	Peroxisome Proliferator-activated Receptor-Î± Regulates Lipid Homeostasis, but Is Not Associated with Obesity. Journal of Biological Chemistry, 2001, 276, 39088-39093.	1.6	119
669	Improved Lipid and Lipoprotein Profile, Hepatic Insulin Sensitivity, and Glucose Tolerance in 11Î²-Hydroxysteroid Dehydrogenase Type 1 Null Mice. Journal of Biological Chemistry, 2001, 276, 41293-41300.	1.6	395
670	Human ABCA1 BAC Transgenic Mice Show Increased High Density Lipoprotein Cholesterol and ApoAI-dependent Efflux Stimulated by an Internal Promoter Containing Liver X Receptor Response Elements in Intron 1. Journal of Biological Chemistry, 2001, 276, 33969-33979.	1.6	176
671	Induction of the Phospholipid Transfer Protein Gene Accounts for the High Density Lipoprotein Enlargement in Mice Treated with Fenofibrate. Journal of Biological Chemistry, 2001, 276, 25841-25847.	1.6	84
672	PPAR-Â-Null Mice Are Protected From High-Fat Diet-Induced Insulin Resistance. Diabetes, 2001, 50, 2809-2814.	0.3	228
673	Transcriptional Regulation of Apolipoprotein C-III Gene Expression by the Orphan Nuclear Receptor RORÎ±. Journal of Biological Chemistry, 2001, 276, 2865-2871.	1.6	129
674	PPARÎ± Agonists Inhibit Tissue Factor Expression in Human Monocytes and Macrophages. Circulation, 2001, 103, 207-212.	1.6	197
675	Peroxisome Proliferator-activated Receptor Î± Is Not Rate-limiting for the Lipoprotein-lowering Action of Fish Oil. Journal of Biological Chemistry, 2001, 276, 4634-4639.	1.6	70
676	The OSBP-related protein family in humans. Journal of Lipid Research, 2001, 42, 1203-1213.	2.0	177
677	Statin-induced inhibition of the Rho-signaling pathway activates PPARÎ± and induces HDL apoA-I. Journal of Clinical Investigation, 2001, 107, 1423-1432.	3.9	381
678	Nouvelles conceptions sur le mode dâ€™action des fibrates et prospectives thÃ©rapeutiques de lâ€™athÃ©rosclÃ©rose. Bulletin De L'Academie Nationale De Medecine, 2001, 185, 63-75.	0.0	3
679	PPAR (peroxisome proliferator-activated receptors) et paroi vasculaire : implications dans l'athÃ©rosclÃ©rose.. Medecine/Sciences, 2001, 17, 637.	0.0	0
680	Peroxisome Proliferator-activated Receptor Î± Activators Improve Insulin Sensitivity and Reduce Adiposity. Journal of Biological Chemistry, 2000, 275, 16638-16642.	1.6	554
681	Nuclear transcription factors: new opportunities for lipid lowering. Proceedings of the Nutrition Society, 2000, 59, 433-433.	0.4	1
682	Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochemical Pharmacology, 2000, 60, 1245-1250.	2.0	202
683	Variation in the PPARÎ± gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia, 2000, 43, 673-680.	2.9	180
684	Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflammation Research, 2000, 49, 497-505.	1.6	853

#	Article	IF	Citations
685	Circadian and Glucocorticoid Regulation of Rev-erbÎ± Expression in Liver¹. Endocrinology, 2000, 141, 3799-3806.	1.4	150
686	CLA-1/SR-BI Is Expressed in Atherosclerotic Lesion Macrophages and Regulated by Activators of Peroxisome Proliferator-Activated Receptors. Circulation, 2000, 101, 2411-2417.	1.6	405
687	Induction of IÎºBÎ± Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-Î± Activators. Journal of Biological Chemistry, 2000, 275, 36703-36707.	1.6	417
688	Regulation of Lipid and Lipoprotein Metabolism by PPAR Activators. Clinical Chemistry and Laboratory Medicine, 2000, 38, 3-11.	1.4	225
689	Oxidized phospholipids activate PPARÎ± in a phospholipase A2-dependent manner. FEBS Letters, 2000, 471, 34-38.	1.3	179
690	Peroxisome proliferator-activated receptor Î³ activators inhibit interleukin-12 production in murine dendritic cells. FEBS Letters, 2000, 486, 261-266.	1.3	152
691	Le rÃ1e de ses activateurs dans la rÃ©gulation de l'expression des gÃ¨nes impliquÃ©s dans le mÃ©tabolisme des lipoprotÃ©ines, l'inflammation vasculaire et l'athÃ©rosclÃ©rose. Annales De L'Institut Pasteur / ActualitÃ©s, 2000, 11, 89-106.	0.1	0
692	Induction of MDR2 P-glycoprotein (PGP) by fibrates is mediated by peroxisome proliferator-activated receptor alpha (PPARÎ±) in the mouse. Journal of Hepatology, 2000, 32, 119.	1.8	1
693	PPARs and Atherosclerosis. , 2000, , 88-95.		1
694	Fibrates Suppress Fibrinogen Gene Expression in Rodents Via Activation of the Peroxisome Proliferator-Activated Receptor-îœ€. Blood, 1999, 93, 2991-2998.	0.6	127
695	Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Current Opinion in Lipidology, 1999, 10, 245-258.	1.2	386
696	Fibrates Increase Human REV-ERBÎ± Expression in Liver via a Novel Peroxisome Proliferator-Activated Receptor Response Element. Molecular Endocrinology, 1999, 13, 400-409.	3.7	132
697	A Truncated Human Peroxisome Proliferator-Activated Receptor Î± Splice Variant with Dominant Negative Activity. Molecular Endocrinology, 1999, 13, 1535-1549.	3.7	126
698	Peroxisome Proliferator-Activated Receptor Activators Inhibit Thrombin-Induced Endothelin-1 Production in Human Vascular Endothelial Cells by Inhibiting the Activator Protein-1 Signaling Pathway. Circulation Research, 1999, 85, 394-402.	2.0	489
699	Beneficial Effects of Fibrates on Apolipoprotein A-I Metabolism Occur Independently of Any Peroxisome Proliferative Response. Circulation, 1999, 99, 2445-2451.	1.6	52
700	Developmental and Pharmacological Regulation of Apolipoprotein C-II Gene Expression. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 115-121.	1.1	39
701	No short-term effect of oral isotretinoin (13-cis retinoic acid) on lipoprotein(a) and HDL subclasses LP-A-I and LP-A-I:A-II in healthy volunteers. Journal of Internal Medicine, 1999, 246, 120-122.	2.7	3
702	Protective Role of Interleukin-10 in Atherosclerosis. Circulation Research, 1999, 85, e17-24.	2.0	631

#	Article	IF	Citations
703	The mitochondrion is the principal target for nutritional and pharmacological control of plasma triglyceride. Lipids, 1999, 34, S167-S167.	0.7	3
704	Effects of Pinus pinaster and Pinus koraiensis seed oil supplementation on lipoprotein metabolism in the rat. Lipids, 1999, 34, 39-44.	0.7	176
705	Comparison of expression and regulation of the high-density lipoprotein receptor SR-BI and the low-density lipoprotein receptor in human adrenocortical carcinoma NCI-H295 cells. FEBS Journal, 1999, 261, 481-491.	0.2	56
706	Schistosoma mansoni schistosomula reduce E-selectin and VCAM-1 expression in TNF-Î±-stimulated lung microvascular endothelial cells by interfering with the NF-ÎºB pathway. European Journal of Immunology, 1999, 29, 3691-3701.	1.6	44
707	Peroxisome Proliferator-activated Receptor Î± Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-ÎºB and AP-1. Journal of Biological Chemistry, 1999, 274, 32048-32054.	1.6	982
708	11. Nuclear receptors as targets to modulate HDL levels. Atherosclerosis, 1999, 146, S15.	0.4	0
709	Fibrates suppress bile acid synthesis via PPARÎ±-mediated down-regulation of cholesterol 7Î±-hydroxylase and sterol 27-hydroxylase gene expression. Atherosclerosis, 1999, 144, 23.	0.4	1
710	Effects of F 12511, a potent ACAT inhibitor, on human adrenocortical cells in culture. Atherosclerosis, 1999, 144, 28.	0.4	0
711	Hypolipidemic effects of R103757, a potent stereoselective inhibitor of microsomal triglyceride transfer protein (MTP). Atherosclerosis, 1999, 144, 38.	0.4	4
712	Regulation of CLA-1 (CD36 and limp II analogous I) by activators of peroxisome proliferator activated receptors (PPARS). Atherosclerosis, 1999, 144, 112.	0.4	2
713	Regulation of macrophage lipoprotein lipase expression by activators of peroxisome proliferator-activated receptors. Atherosclerosis, 1999, 144, 146.	0.4	1
714	Cell Culture Conditions Determine Apolipoprotein CIII Secretion and Regulation by Fibrates in Human Hepatoma HepG2 Cells. Cellular Physiology and Biochemistry, 1999, 9, 139-149.	1.1	38
715	Metabolism of Apolipoproteins AI and AII in a Patient with Paradoxical Reduction in High-Density Lipoprotein Due to Ciprofibrate. Annals of Clinical Biochemistry, 1999, 36, 523-525.	0.8	26
716	Peroxisome proliterator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Current Opinion in Lipidology, 1999, 10, 151-160.	1.2	210
717	Fibrates Suppress Fibrinogen Gene Expression in Rodents Via Activation of the Peroxisome Proliferator-Activated Receptor-îœ€. Blood, 1999, 93, 2991-2998.	0.6	39
718	Fibrates Increase Human REV-ERBÂ Expression in Liver via a Novel Peroxisome Proliferator-Activated Receptor Response Element. Molecular Endocrinology, 1999, 13, 400-409.	3.7	87
719	A Truncated Human Peroxisome Proliferator-Activated Receptor Â Splice Variant with Dominant Negative Activity. Molecular Endocrinology, 1999, 13, 1535-1549.	3.7	88
720	La mutation staggerer du rÃ©cepteur nuclÃ©aire RORÎ±, ou comment un phÃ©notype peut en cacher un autre.. Medecine/Sciences, 1999, 15, 1305.	0.0	0

#	Article	IF	Citations
721	Activation of human aortic smooth-muscle cells is inhibited by PPARÎ± but not by PPARÎ³ activators. Nature, 1998, 393, 790-793.	13.7	1,104
722	Leptin. Lancet, The, 1998, 351, 737-742.	6.3	430
723	High level expression of PPARÎ³ in differentiated colon epithelium. Gastroenterology, 1998, 114, A391.	0.6	0
724	Regulation of apo A-I gene expression by fibrates. Atherosclerosis, 1998, 137, S19-S23.	0.4	112
725	PPARÎ³ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis, 1998, 137, S75-S80.	0.4	119
726	Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor Î±-dependent pathway. Toxicology Letters, 1998, 98, 13-23.	0.4	72
727	Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism. Circulation, 1998, 98, 2088-2093.	1.6	1,540
728	Activation of Proliferator-activated Receptors Î± and Î³ Induces Apoptosis of Human Monocyte-derived Macrophages. Journal of Biological Chemistry, 1998, 273, 25573-25580.	1.6	837
729	The Nuclear Receptors Peroxisome Proliferator-activated Receptor Î± and Rev-erbÎ± Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates. Journal of Biological Chemistry, 1998, 273, 25713-25720.	1.6	270
730	Severe Atherosclerosis and Hypoalphalipoproteinemia in the Staggerer Mouse, a Mutant of the Nuclear Receptor RORÎ±. Circulation, 1998, 98, 2738-2743.	1.6	166
731	Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.. Journal of Clinical Investigation, 1998, 102, 625-632.	3.9	120
732	Mechanisms of the Hypolipidemic Action of Fibrates. Medical Science Symposia Series, 1998, , 9-17.	0.0	0
733	Transcription of the Human Genes for Cytochrome P450scc and P450c17 Is Regulated Differently in Human Adrenal NCI-H295 Cells Than in Mouse Adrenal Y1 Cells1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 365-371.	1.8	81
734	Transcriptional Regulation of Apolipoprotein A-I Gene Expression by the Nuclear Receptor RORÎ±. Journal of Biological Chemistry, 1997, 272, 22401-22404.	1.6	127
735	The Organization, Promoter Analysis, and Expression of the Human PPARÎ³ Gene. Journal of Biological Chemistry, 1997, 272, 18779-18789.	1.6	1,034
736	Coordinate Regulation of the Expression of the Fatty Acid Transport Protein and Acyl-CoA Synthetase Genes by PPARÎ± and PPARÎ³ Activators. Journal of Biological Chemistry, 1997, 272, 28210-28217.	1.6	464
737	Peroxisome proliterator-activated receptors, orphans with ligands and functions. Current Opinion in Lipidology, 1997, 8, 159-166.	1.2	455
738	Alterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor Î±-deficient Mice. Journal of Biological Chemistry, 1997, 272, 27307-27312.	1.6	388

#	Article	IF	Citations
739	4.P.304 HDL (high density lipoprotein) and LDL (low density lipoprotein) receptors regulation in human adrenal cortex. Atherosclerosis, 1997, 134, 360.	0.4	0
740	4.P.367 Transcription factor genes controlling high density lipoprotein metabolism. Atherosclerosis, 1997, 134, 374.	0.4	0
741	4.P.263 Coordinate regulation of the expression of the fatty acid transporter protein (FATP) and acyl CoA synthetase (ACS) genes by PPARÎ± and PPARÎ³ activators. Atherosclerosis, 1997, 134, 351.	0.4	0
742	1.P.174 The mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism. Atherosclerosis, 1997, 134, 53.	0.4	0
743	1.P.194 Thiazolidinediones exert a hypotriglyceridemic effect by a distinct, but complementary mechanism relative to fibrates. Atherosclerosis, 1997, 134, 57-58.	0.4	1
744	1.P.199 The underlying mechanism of the hypolipidemic effect of 3-thia fatty acids. Atherosclerosis, 1997, 134, 58-59.	0.4	0
745	2.P.139 Effects of oral isotretinoin (13-cis retinoic acid) on lipoprotein(a) and HDL subclasses lpA-I and lpA-I: A-II in healthy volunteers. Atherosclerosis, 1997, 134, 145.	0.4	0
746	The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs). Biochimie, 1997, 79, 95-99.	1.3	71
747	Cycle Sequencing on Large DNA Templates. BioTechniques, 1997, 23, 1034-1036.	0.8	10
748	Regulation of Lipoprotein Metabolism by Thiazolidinediones Occurs through a Distinct but Complementary Mechanism Relative to Fibrates. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1756-1764.	1.1	142
749	Transcription of the Human Genes for Cytochrome P450scc and P450c17 Is Regulated Differently in Human Adrenal NCI-H295 Cells Than in Mouse Adrenal Y1 Cells. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 365-371.	1.8	60
750	Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes, 1997, 46, 1319-1327.	0.3	171
751	RÃ1e des cofacteurs transcriptionnels dans la transduction des signaux hormonaux par les rÃ©cepteurs nuclÃ©aires.. Medecine/Sciences, 1997, 13, 961.	0.0	0
752	The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Lipids and Lipid Metabolism, 1996, 1302, 93-109.	2.6	900
753	Transcription, adipocyte differentiation, and obesity. Journal of Molecular Medicine, 1996, 74, 347-352.	1.7	67
754	Growth hormone normalizes low-density lipoprotein receptor gene expression in hypothyroid rats. Metabolism: Clinical and Experimental, 1996, 45, 680-685.	1.5	14
755	Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis, 1996, 124, S29-S37.	0.4	140
756	Regulation of Triglyceride Metabolism by PPARs : Fibrates and Thiazolidinediones have Distinct Effects. Journal of Atherosclerosis and Thrombosis, 1996, 3, 81-89.	0.9	104

#	Article	IF	Citations
757	Two regulatory elements of similar structure and placed in tandem account for the repressive activity of the first intron of the human apolipoprotein A-II gene. Biochemical Journal, 1996, 318, 547-553.	1.7	16
758	The adipocyte specific transcription factor C/EBPalpha modulates human ob gene expression.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 5507-5511.	3.3	139
759	New insights into obesity genes. Diabetologia, 1996, 39, 1528-1531.	2.9	6
760	Transcriptional Induction of Rat Liver Apolipoprotein A-I Gene Expression by Glucocorticoids Requires the Glucocorticoid Receptor and a Labile Cell-Specific Protein. FEBS Journal, 1996, 239, 451-459.	0.2	26
761	PPAR Tissue Distribution and Interactions with Other Hormone-Signaling Pathways. Annals of the New York Academy of Sciences, 1996, 804, 231-251.	1.8	149
762	Expression and Regulation of the Lipoprotein Lipase Gene in Human Adrenal Cortex. Journal of Biological Chemistry, 1996, 271, 17425-17432.	1.6	10
763	Expression of the Peroxisome Proliferator-activated Receptor Î± Gene Is Stimulated by Stress and Follows a Diurnal Rhythm. Journal of Biological Chemistry, 1996, 271, 1764-1769.	1.6	291
764	Regulation of OB Gene Expression in Rodents and Humans. Hormone and Metabolic Research, 1996, 28, 638-641.	0.7	38
765	Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.. Journal of Clinical Investigation, 1996, 97, 2408-2416.	3.9	230
766	The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue.. Journal of Clinical Investigation, 1996, 98, 251-255.	3.9	162
767	Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma.. Journal of Clinical Investigation, 1996, 98, 1004-1009.	3.9	318
768	Les facteurs rÃ©gulateurs du gÃ¨ne ob. Medecine/Sciences, 1996, 12, 383.	0.0	0
769	Transcription, diffÃ©renciation adipocytaire et obÃ©sitÃ©. Medecine/Sciences, 1996, 12, 885.	0.0	0
770	Induction of the Acyl-Coenzyme A Synthetase Gene by Fibrates and Fatty Acids Is Mediated by a Peroxisome Proliferator Response Element in the C Promoter. Journal of Biological Chemistry, 1995, 270, 19269-19276.	1.6	344
771	Regulation of Rat Liver Apolipoprotein A-I, Apolipoprotein A-II and Acyl-Coenzyme A Oxidase Gene Expression by Fibrates and Dietary Fatty Acids. FEBS Journal, 1995, 232, 179-187.	0.2	121
772	Transient increase in obese gene expression after food intake or insulin administration. Nature, 1995, 377, 527-528.	13.7	1,063
773	Localization of the Human OB Gene (OBS) to Chromosome 7q32 by Fluorescence in Situ Hybridization. Genomics, 1995, 28, 603-604.	1.3	26
774	Induction of ob Gene Expression by Corticosteroids Is Accompanied by Body Weight Loss and Reduced Food Intake. Journal of Biological Chemistry, 1995, 270, 15958-15961.	1.6	410

#	Article	IF	Citations
775	Tissue-specific Expression of the Human Gene for Lecithin: Cholesterol Acyltransferase in Transgenic Mice Alters Blood Lipids, Lipoproteins and Lipases towards a Less Atherogenic Profile. FEBS Journal, 1995, 230, 567-575.	0.2	53
776	Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.. Journal of Clinical Investigation, 1995, 95, 705-712.	3.9	381
777	Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.. Journal of Clinical Investigation, 1995, 96, 741-750.	3.9	350
778	Opposite in vitro and in vivo regulation of hepatic apolipoprotein A-I gene expression by retinoic acid. Absence of effects on apolipoprotein A-II gene expression.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 1657-1664.	3.8	32
779	Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation. FEBS Journal, 1993, 216, 615-622.	0.2	100
780	Growth hormone normalizes hepatic lipase in hypothyroid rat liver. Metabolism: Clinical and Experimental, 1993, 42, 669-671.	1.5	5
781	Developmental extinction of liver lipoprotein lipase mRNA expression might be regulated by an NF-1-like site. FEBS Letters, 1993, 329, 89-95.	1.3	21
782	Effects of Sex Steroids on Hepatic and Lipoprotein Lipase Activity and mRNA in the Rat. Hormone Research, 1993, 40, 184-188.	1.8	26
783	Regulation of steroidogenesis in NCI-H295 cells: a cellular model of the human fetal adrenal. Molecular Endocrinology, 1993, 7, 423-433.	3.7	93
784	Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992, 12, 286-294.	3.8	142
785	Lipoprotein lipase expression in undifferentiated hepatoma cells is regulated by progesterone and protein kinase A. Biochemistry, 1992, 31, 10121-10128.	1.2	15
786	Down-regulation of hepatic lipase gene expression and activity by fenofibrate. Lipids and Lipid Metabolism, 1992, 1123, 227-230.	2.6	32
787	Opposite regulation of hepatic lipase and lecithin: cholesterol acyltransferase by glucocorticoids in rats. Lipids and Lipid Metabolism, 1992, 1128, 181-185.	2.6	34
788	Neonatal extinction of liver lipoprotein lipase expression. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1992, 1131, 281-286.	2.4	30
789	Changes in IgG Fc receptor expression induced by phorbol 12-myristate 13-acetate treatment of THP-1 monocytic leukemia cells. Leukemia Research, 1992, 16, 317-327.	0.4	43
790	The effects of probucol on lipoprotein metabolism in the rat. Lipids and Lipid Metabolism, 1991, 1085, 131-135.	2.6	8
791	Variable effects of different corticosteroids on plasma lipids, apolipoproteins, and hepatic apolipoprotein mRNA levels in rats.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991, 11, 760-769.	3.8	58
792	Increased removal of beta-very low density lipoproteins after ethinyl estradiol is associated with increased mRNA levels for hepatic lipase, lipoprotein lipase, and the low density lipoprotein receptor in Watanabe heritable hyperlipidemic rabbits.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991, 11, 1652-1659.	3.8	18

#	Article	IF	Citations
793	Activation of junB by PKC and PKA signal transduction through a novelcis-acting element. Nucleic Acids Research, 1991, 19, 775-781.	6.5	95
794	Alterations in Thyroid Status Modulate Apolipoprotein, Hepatic Triglyceride Lipase, and Low Density Lipoprotein Receptor in Rats*. Endocrinology, 1990, 127, 1144-1152.	1.4	129
795	Coupled and uncoupled induction of fos and jun transcription by different second messengers in cells of hematopoietic origin. Nucleic Acids Research, 1990, 18, 221-228.	6.5	74
796	Apolipoprotein A-IV Messenger Ribonucleic Acid Abundance Is Regulated in a Tissue-Specific Manner*. Endocrinology, 1990, 126, 2153-2163.	1.4	66